<?xml version='1.0' encoding='utf-8'?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1" xmlns:video="http://www.google.com/schemas/sitemap-video/1.1"><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/gss-genetic-signatures-microba-merger-bcal-support-november-2026-6dwjf</loc><lastmod>2026-11-19</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/9e267f8d-545b-4cf7-b8fa-219927ebd5eb.jpg</video:thumbnail_loc><video:title>Genetic Signatures Top Holder Open to Merger Revival on Tougher Terms [VIDEO]</video:title><video:description>BCAL Diagnostics, the largest Genetic Signatures shareholder, says it will back a revised Genetic Signatures Microba merger only if it gets a 60:40 split and a Board shake-up.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/76bd257a-5efa-457a-a5fe-5a391a905d49.mp4</video:content_loc><video:publication_date>2026-11-19T04:35:19.367905Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/gss-genetic-signatures-microba-merger-bcal-support-november-2026</loc><lastmod>2026-11-19</lastmod><image:image><image:loc>https://media.stockwirex.com/articles/media/featured_image/65ea0e70-d212-45ee-96c4-930e516d3b56.jpg</image:loc><image:title>Genetic Signatures Top Holder Open to Merger Revival on Tougher Terms</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/377e0890-f0e9-4069-b29d-04f2290972f4.jpg</video:thumbnail_loc><video:title>Genetic Signatures Top Holder Open to Merger Revival on Tougher Terms</video:title><video:description>BCAL Diagnostics, the largest Genetic Signatures shareholder, says it will back a revised Genetic Signatures Microba merger only if it gets a 60:40 split and a Board shake-up.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/9cce3804-d432-4320-b71b-f16060cd1614.mp4</video:content_loc><video:publication_date>2026-11-19T03:53:03.759806Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/snt-syntara-amsulostat-myelofibrosis-update-november-2026-phuef</loc><lastmod>2026-11-19</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/27fb90b0-66b0-461c-bc63-f733b85d0b51.jpg</video:thumbnail_loc><video:title>Syntara Lays Out a Path for Amsulostat With Cash Into CY28 [VIDEO]</video:title><video:description>Syntara's amsulostat myelofibrosis update shows $14.1 million in cash lasting into 2028 and a bigger trial planned for the first half of 2027.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/108b7263-4b64-4d13-ad60-bf9b55bbc1c1.mp4</video:content_loc><video:publication_date>2026-11-19T01:48:37.724504Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/snt-syntara-amsulostat-myelofibrosis-update-november-2026</loc><lastmod>2026-11-19</lastmod><image:image><image:loc>https://media.stockwirex.com/articles/media/featured_image/7980cf16-442c-4ff0-961e-1eb22d225e40.jpg</image:loc><image:title>Syntara Lays Out a Path for Amsulostat With Cash Into CY28</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/75fb8266-9ce4-4dc1-a66f-cbcf4be3614a.jpg</video:thumbnail_loc><video:title>Syntara Lays Out a Path for Amsulostat With Cash Into CY28</video:title><video:description>Syntara's amsulostat myelofibrosis update shows $14.1 million in cash lasting into 2028 and a bigger trial planned for the first half of 2027.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/9ee6346e-41a4-4dfa-817b-d268b7f695b0.mp4</video:content_loc><video:publication_date>2026-11-19T01:10:14.180207Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/gss-genetic-signatures-microba-merger-terminated-november-2026-ekk74</loc><lastmod>2026-11-18</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/47721ec8-8386-453a-b908-972f4c9bba41.jpg</video:thumbnail_loc><video:title>Genetic Signatures Walks Away From Microba Merger Over Funding Gap [VIDEO]</video:title><video:description>The Microba Genetic Signatures merger is off after Microba said it cannot fund the deal without more capital, leaving its shares suspended from trading.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/b2f8474b-e580-451b-9d9f-5922e0f1587b.mp4</video:content_loc><video:publication_date>2026-11-18T03:04:01.700021Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/gss-genetic-signatures-microba-merger-terminated-november-2026</loc><lastmod>2026-11-18</lastmod><image:image><image:loc>https://media.stockwirex.com/articles/media/featured_image/58ef5c91-313c-4491-9d85-641f2bc66b5d.jpg</image:loc><image:title>Genetic Signatures Walks Away From Microba Merger Over Funding Gap</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/fffeeb94-afba-4e72-bafd-fb30addef6a9.jpg</video:thumbnail_loc><video:title>Genetic Signatures Walks Away From Microba Merger Over Funding Gap</video:title><video:description>The Microba Genetic Signatures merger is off after Microba said it cannot fund the deal without more capital, leaving its shares suspended from trading.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/013ff5fe-c0a4-4258-80d9-49d0e3cbe4a2.mp4</video:content_loc><video:publication_date>2026-11-18T02:25:20.031913Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/idt-australia-fy27-earnings-guidance-november-2026-9rqgn</loc><lastmod>2026-11-18</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/b6e1dfbc-3d6e-49be-b8eb-f4c5bf2db0ce.jpg</video:thumbnail_loc><video:title>IDT Australia Guides to Positive FY27 EBITDA on $19M to $20M Revenue [VIDEO]</video:title><video:description>IDT Australia FY27 earnings guidance points to revenue of $19 million to $20 million and a return to profit, backed by larger contracts and a $7 million facilities upgrade.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/c6cc9ca1-e476-4f50-9e4d-a9be95c84190.mp4</video:content_loc><video:publication_date>2026-11-18T00:59:55.045824Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/gss-genetic-signatures-microba-merger-termination-november-2026-2r95h</loc><lastmod>2026-11-18</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/dc5aeb86-3a11-4d82-bfbd-f9e91e392ff1.jpg</video:thumbnail_loc><video:title>Genetic Signatures Walks Away From Microba Merger Over Funding Gap [VIDEO]</video:title><video:description>Genetic Signatures has ended its proposed merger with Microba Life Sciences after Microba said it could not finish the deal without more capital, a Genetic Signatures Microba merger termination that leaves a Takeovers Panel application still to be resolved.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/81ace707-57cf-4c6d-8f72-4ff16ec05956.mp4</video:content_loc><video:publication_date>2026-11-18T00:59:54.320608Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/idt-australia-fy27-earnings-guidance-november-2026</loc><lastmod>2026-11-18</lastmod><image:image><image:loc>https://media.stockwirex.com/articles/media/featured_image/627b777d-f48d-4ece-ab35-56ad3633aa20.jpg</image:loc><image:title>IDT Australia Guides to Positive FY27 EBITDA on $19M to $20M Revenue</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/6db40c61-0dc2-4bb9-aa72-fb3ac1dcc8dd.jpg</video:thumbnail_loc><video:title>IDT Australia Guides to Positive FY27 EBITDA on $19M to $20M Revenue</video:title><video:description>IDT Australia FY27 earnings guidance points to revenue of $19 million to $20 million and a return to profit, backed by larger contracts and a $7 million facilities upgrade.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/a39a260e-8600-4457-8ea2-b1bd2b02b100.mp4</video:content_loc><video:publication_date>2026-11-18T00:19:53.894310Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/gss-genetic-signatures-microba-merger-termination-november-2026</loc><lastmod>2026-11-18</lastmod><image:image><image:loc>https://media.stockwirex.com/articles/media/featured_image/8bb3a405-4ff7-4777-a04f-b335d23e0530.jpg</image:loc><image:title>Genetic Signatures Walks Away From Microba Merger Over Funding Gap</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/87f6dff3-386a-4201-be52-a33435162816.jpg</video:thumbnail_loc><video:title>Genetic Signatures Walks Away From Microba Merger Over Funding Gap</video:title><video:description>Genetic Signatures has ended its proposed merger with Microba Life Sciences after Microba said it could not finish the deal without more capital, a Genetic Signatures Microba merger termination that leaves a Takeovers Panel application still to be resolved.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/480c1d74-1d67-40d1-a732-32d7dec68de9.mp4</video:content_loc><video:publication_date>2026-11-18T00:19:53.884817Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imu-imugene-rd-tax-refund-november-2026-8nlrb</loc><lastmod>2026-11-15</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/4ba78e0a-751a-489d-9808-0494386d1b66.jpg</video:thumbnail_loc><video:title>Imugene Banks a $2.1M Tax Refund to Fund Its Azer-cel Patient Hunt [VIDEO]</video:title><video:description>Imugene has received a $2.1 million R&amp;D tax refund from the Australian Government, which will help recruit patients for its azer-cel cancer study.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/fd9d3b28-5842-4810-9bba-fe51e53af7f1.mp4</video:content_loc><video:publication_date>2026-11-15T22:52:51.153553Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imu-imugene-rd-tax-refund-november-2026</loc><lastmod>2026-11-15</lastmod><image:image><image:loc>https://media.stockwirex.com/articles/media/featured_image/a9391388-1112-40d3-ba8f-2a7eda92b5c3.jpg</image:loc><image:title>Imugene Banks a $2.1M Tax Refund to Fund Its Azer-cel Patient Hunt</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/b2a615e8-7086-4678-bceb-c5a4c3c47313.jpg</video:thumbnail_loc><video:title>Imugene Banks a $2.1M Tax Refund to Fund Its Azer-cel Patient Hunt</video:title><video:description>Imugene has received a $2.1 million R&amp;D tax refund from the Australian Government, which will help recruit patients for its azer-cel cancer study.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/adb5948f-f356-450a-9df8-adda272a4249.mp4</video:content_loc><video:publication_date>2026-11-15T22:16:56.121288Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imu-imugene-azer-cel-clinical-progress-november-2026-mch74</loc><lastmod>2026-11-11</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/8073de76-2cc7-44d8-a9df-5659e8521e0a.jpg</video:thumbnail_loc><video:title>Imugene Azer-cel Posts 77% Response in 56 Phase 1b Patients [VIDEO]</video:title><video:description>Imugene azer-cel clinical progress now spans 140 treated patients, a 77% response rate in the later trial and a cost base cut by about 40%.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/c88949e9-2f4b-4744-bd8f-9c68a86ba0a7.mp4</video:content_loc><video:publication_date>2026-11-11T05:42:58.621301Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imu-imugene-azer-cel-clinical-progress-november-2026</loc><lastmod>2026-11-11</lastmod><image:image><image:loc>https://media.stockwirex.com/articles/media/featured_image/a5167ca4-8a33-4811-86b3-81afa0161929.jpg</image:loc><image:title>Imugene Azer-cel Posts 77% Response in 56 Phase 1b Patients</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/0d6b8423-ed8b-466e-8f7c-a429cbc2bf93.jpg</video:thumbnail_loc><video:title>Imugene Azer-cel Posts 77% Response in 56 Phase 1b Patients</video:title><video:description>Imugene azer-cel clinical progress now spans 140 treated patients, a 77% response rate in the later trial and a cost base cut by about 40%.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/e5c3d6fd-b948-4fb8-a501-f52fccbc6ce0.mp4</video:content_loc><video:publication_date>2026-11-11T05:03:39.021230Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imc-immuron-ltd-lifesci-capital-strategic-review-november-2026-trol8</loc><lastmod>2026-11-10</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/55e483f5-3e79-4bd1-a299-402d27733297.jpg</video:thumbnail_loc><video:title>Immuron Hires LifeSci Capital to Explore Mergers and Other Deals [VIDEO]</video:title><video:description>Immuron has named LifeSci Capital as its exclusive financial advisor for a strategic review that could lead to mergers, acquisitions or licensing deals.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/8d72c13d-d5d0-4ce9-aa56-7d7dda5b697d.mp4</video:content_loc><video:publication_date>2026-11-10T06:26:19.564734Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imc-immuron-ltd-lifesci-capital-strategic-review-november-2026</loc><lastmod>2026-11-10</lastmod><image:image><image:loc>https://media.stockwirex.com/articles/media/featured_image/b4f85adc-cb23-4851-95b9-055c4e974fd4.jpg</image:loc><image:title>Immuron Hires LifeSci Capital to Explore Mergers and Other Deals</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/345b896c-dc41-49fe-9a33-c2e05471a994.jpg</video:thumbnail_loc><video:title>Immuron Hires LifeSci Capital to Explore Mergers and Other Deals</video:title><video:description>Immuron has named LifeSci Capital as its exclusive financial advisor for a strategic review that could lead to mergers, acquisitions or licensing deals.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/00281660-8e49-460c-9f4a-d8d4ee0e4f0d.mp4</video:content_loc><video:publication_date>2026-11-10T05:49:29.681343Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/snt-syntara-ltd-snt-9465-trial-recruitment-pause-november-2026-qwynp</loc><lastmod>2026-11-09</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/9cb207c6-1edd-408d-9c30-aa03a0241ce0.jpg</video:thumbnail_loc><video:title>Syntara Pauses Scar Trial Recruitment After Skin Irritation Reports [VIDEO]</video:title><video:description>Syntara has paused recruitment in its SNT-9465 Phase 1b scar study after reports of mild to moderate skin irritation, and will decide this quarter whether the study restarts or ends.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/72536d03-4383-4fba-bf71-46d766bc5942.mp4</video:content_loc><video:publication_date>2026-11-09T23:42:05.154966Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/snt-syntara-ltd-snt-9465-trial-recruitment-pause-november-2026</loc><lastmod>2026-11-09</lastmod><image:image><image:loc>https://media.stockwirex.com/articles/media/featured_image/7cf7bc54-9ede-4ea4-86ce-2cb8ccc8fdbb.jpg</image:loc><image:title>Syntara Pauses Scar Trial Recruitment After Skin Irritation Reports</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/33b26536-96ba-4786-ae18-610fde2d4840.jpg</video:thumbnail_loc><video:title>Syntara Pauses Scar Trial Recruitment After Skin Irritation Reports</video:title><video:description>Syntara has paused recruitment in its SNT-9465 Phase 1b scar study after reports of mild to moderate skin irritation, and will decide this quarter whether the study restarts or ends.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/110e0c51-84db-452a-8bb4-d4aa0d7b9c96.mp4</video:content_loc><video:publication_date>2026-11-09T23:05:19.544449Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imu-imugene-azer-cel-ash-poster-presentation-november-2026-c5s1a</loc><lastmod>2026-11-05</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/76b4cd15-360d-4b37-a992-a81db108c501.jpg</video:thumbnail_loc><video:title>Imugene Wins an ASH Poster Slot to Show Its Azer-Cel Lymphoma Data [VIDEO]</video:title><video:description>Imugene's blood cancer therapy azer-cel will be shown as a poster at the American Society of Hematology meeting in New Orleans on 13 December 2026, in this Imugene azer-cel ASH poster presentation update.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/487c5143-6964-4beb-baa7-58636294fa68.mp4</video:content_loc><video:publication_date>2026-11-05T05:23:02.122672Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imu-imugene-azer-cel-ash-poster-presentation-november-2026</loc><lastmod>2026-11-05</lastmod><image:image><image:loc>https://media.stockwirex.com/articles/media/featured_image/55910d54-d1c2-4eac-a390-fa468881256e.jpg</image:loc><image:title>Imugene Wins an ASH Poster Slot to Show Its Azer-Cel Lymphoma Data</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/17065357-f89e-49fb-82a7-32c8feee5ae5.jpg</video:thumbnail_loc><video:title>Imugene Wins an ASH Poster Slot to Show Its Azer-Cel Lymphoma Data</video:title><video:description>Imugene's blood cancer therapy azer-cel will be shown as a poster at the American Society of Hematology meeting in New Orleans on 13 December 2026, in this Imugene azer-cel ASH poster presentation update.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/7d642591-1aa2-41d8-891a-db6bcae8f107.mp4</video:content_loc><video:publication_date>2026-11-05T04:45:36.250105Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/fct-firstwave-cloud-technology-open-audit-7-enterprise-trial-november-2026-af0gj</loc><lastmod>2026-11-04</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/c58d062a-01d3-4796-a7ce-f0eb48aaa141.jpg</video:thumbnail_loc><video:title>FirstWave Gives Every Open-AudIT Download a 30-Day Enterprise Trial [VIDEO]</video:title><video:description>FirstWave has launched Open-AudIT 7.0.0, and every download now comes with a 30-day full Enterprise trial for unlimited devices, a new way to turn free users into paying ones.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/25754826-cb26-4d7a-aabc-26d86a17fca2.mp4</video:content_loc><video:publication_date>2026-11-04T00:11:25.278944Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imu-imugene-cvi-convertible-notes-amendments-november-2026-a2d3d</loc><lastmod>2026-11-03</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/0175bf7e-3f22-4896-9a77-8519c31ad90d.jpg</video:thumbnail_loc><video:title>Imugene Gains Conditional Right to Redeem CVI Convertible Notes [VIDEO]</video:title><video:description>Imugene has agreed changes with CVI Investments that give it a conditional right to repay two sets of convertible notes early, but only with the lender's written consent.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/96b84e73-42f3-4bfe-a561-c9704cf76ad0.mp4</video:content_loc><video:publication_date>2026-11-03T09:45:38.154403Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/vr1-vection-technologies-quarterly-cash-report-october-2026-4evyi</loc><lastmod>2026-10-30</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/c3217cd8-31ed-40ba-a9a6-72942989446d.jpg</video:thumbnail_loc><video:title>Vection Lifts Q1 FY27 Customer Receipts 29% as Operating Outflow Narrows [VIDEO]</video:title><video:description>Vection Technologies' quarterly cash report shows customer receipts up 29% to $6.4 million and cash going out from operations cut to just $0.2 million.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/d0f5b4ea-4c10-499d-bdd3-a314db09e0e1.mp4</video:content_loc><video:publication_date>2026-10-30T00:29:45.574728Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imu-imugene-azer-cel-quarterly-report-october-2026-bpymi</loc><lastmod>2026-10-30</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/f5e3cf9d-48c8-429f-9e89-a5f39adbe824.jpg</video:thumbnail_loc><video:title>Imugene Azer-cel Posts 86% Response Rate in Early Cohort 3 Data [VIDEO]</video:title><video:description>Imugene's azer-cel quarterly report shows six of seven patients responding in its newest trial group, while cash fell to about $5.25 million.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/0352d421-d2d3-494c-bcdc-0cbab39240b2.mp4</video:content_loc><video:publication_date>2026-10-30T00:28:05.397879Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/gss-genetic-signatures-microba-merger-board-appointment-october-2026-0ubwt</loc><lastmod>2026-10-28</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/22eb733a-9ff0-4636-8f7a-0b225f32f269.jpg</video:thumbnail_loc><video:title>Genetic Signatures Adds Former CEO to Board as BCAL Questions Merger [VIDEO]</video:title><video:description>Dr John Melki is back on the GSS Board, but BCAL's fight over the 40/60 Genetic Signatures Microba merger split is far from settled ahead of the 16 November AGM.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/05856435-441f-40cb-83a9-fba54705edb2.mp4</video:content_loc><video:publication_date>2026-10-28T06:02:09.332857Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imc-immuron-travelan-sales-growth-q1-fy27-october-2026-vg44x</loc><lastmod>2026-10-26</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/ad1a6882-e8ed-4ad0-8d49-6dcf818a8dfe.jpg</video:thumbnail_loc><video:title>Immuron Posts $2.2M Q1 FY27 Sales as Travelan Relaunch Lifts Australia 14% [VIDEO]</video:title><video:description>Immuron Travelan sales growth powered a 9% lift in Q1 FY27 sales to $2.2 million, with Australia up 14% and Canada surging 286% even as the US slipped 19%.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/1d757b85-bc28-401e-b021-a0a0ab5785ed.mp4</video:content_loc><video:publication_date>2026-10-26T23:05:56.684532Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/real-estate/aeg-aland-equity-group-villa-estate-cowra-construction-october-2026-7mykg</loc><lastmod>2026-10-20</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/c734ba03-08c5-4c3c-84c6-58d7c5a14408.jpg</video:thumbnail_loc><video:title>Aland Equity Group Breaks Ground on 107-Villa Seniors Estate as Builders Line Up [VIDEO]</video:title><video:description>Aland Equity Villa Estate Cowra moves from planning to dirt as Huon Contractors begins moving more than 100,000 cubic metres of earth for a 107-villa seniors community, with Burbank Homes due to start building in December 2026.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/fa392c40-44ee-4b37-902d-7914edbc5c9a.mp4</video:content_loc><video:publication_date>2026-10-20T22:05:22.869776Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/snt-syntara-snt-4728-phase-2-results-october-2026-bedrock-test-e5fz8</loc><lastmod>2026-10-08</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/d80e10ce-eeeb-4f20-ac47-1dc4048e8a71.jpg</video:thumbnail_loc><video:title>TEST - Syntara Drug Slows Motor Decline in Early Parkinson's Risk Group, Placebo Worsens [VIDEO]</video:title><video:description>Syntara SNT-4728 Parkinson's Phase 2 results show a statistically significant motor improvement (p=0.021) that held 12 weeks after dosing, backing up earlier evidence of reduced brain inflammation.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/6eb3345b-74fe-49ca-9bbd-50794eb564fa.mp4</video:content_loc><video:publication_date>2026-10-08T21:57:09.175041Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/snt-syntara-snt-4728-phase-2-results-october-2026-bedrock-test</loc><lastmod>2026-10-07</lastmod><video:video><video:thumbnail_loc>https://media.stockwirex.com/articles/media/video_thumb/581090a2-aaba-4d3e-9a81-b9d8d915ba1f.jpg</video:thumbnail_loc><video:title>TEST - Syntara Drug Slows Motor Decline in Early Parkinson's Risk Group, Placebo Worsens [VIDEO]</video:title><video:description>Syntara SNT-4728 Parkinson's Phase 2 results show a statistically significant motor improvement (p=0.021) that held 12 weeks after dosing, backing up earlier evidence of reduced brain inflammation.</video:description><video:content_loc>https://media.stockwirex.com/articles/media/video_url/e7a675c9-4f41-45af-bd5a-065b46f03a94.mp4</video:content_loc><video:publication_date>2026-10-07T09:56:30.663436Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/fct-firstwave-cloud-technology-ai-network-patent-september-2026</loc><lastmod>2026-09-04</lastmod><image:image><image:loc>https://media.stockwirex.com/Data-Center-Display-scaled.jpg</image:loc><image:title>Firstwave Cloud Technology Ltd Files AI Network Fault Diagnosis Patent</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/Data-Center-Display-scaled.jpg</video:thumbnail_loc><video:title>Firstwave Cloud Technology Ltd Files AI Network Fault Diagnosis Patent</video:title><video:description>FirstWave Cloud Technology (ASX: FCT) has filed a provisional patent for an AI-driven network fault diagnosis system targeting the on-premise segment that cloud AI cannot reach — built on the network monitoring line that already grew 34% to A$6.9 million in FY26.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F5d88821a-0cb2-414d-959e-1d59d951ba4b.mp4.mp4</video:content_loc><video:publication_date>2026-09-04T09:04:58Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/hfy-hubify-fy26-investor-presentation-september-2026</loc><lastmod>2026-09-04</lastmod><image:image><image:loc>https://media.stockwirex.com/data_center_hfy-scaled.jpg</image:loc><image:title>Hubify Ltd Frames 89% EBITDA Lift Around AI First Managed Intelligence Pivot</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/data_center_hfy-scaled.jpg</video:thumbnail_loc><video:title>Hubify Ltd Frames 89% EBITDA Lift Around AI First Managed Intelligence Pivot</video:title><video:description>Hubify's FY26 investor presentation reveals an 89% EBITDA lift to $0.66m, a 315% surge in net operating cash, and a strategic pivot from Managed Service Provider to AI-first Managed Intelligence Provider — here's what investors need to know.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fafa8ef0a-1443-4dfb-a2d6-89699a03ef83.mp4.mp4</video:content_loc><video:publication_date>2026-09-04T08:24:59Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imc-immuron-proibs-us-distribution-deal-september-2026</loc><lastmod>2026-09-04</lastmod><image:image><image:loc>https://media.stockwirex.com/IMC-Store-Display-scaled.jpg</image:loc><image:title>Immuron Ltd Secures Exclusive US Distribution Rights for PROIBS in $4.16B Market</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/IMC-Store-Display-scaled.jpg</video:thumbnail_loc><video:title>Immuron Ltd Secures Exclusive US Distribution Rights for PROIBS in $4.16B Market</video:title><video:description>Immuron's exclusive Immuron PROIBS US Distribution Deal with Calmino group AB targets a slice of the $4.16 billion US gut health market, backed by a decade of Swedish pharmacy sales and 94% user satisfaction from a 1,003-person study.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F0a20a6ac-77fd-4f22-aad0-a59ead72f3a1-1.mp4-1.mp4</video:content_loc><video:publication_date>2026-09-04T07:49:40Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/real-estate/aeg-aland-equity-group-elm-grove-heights-management-rights-august-2026</loc><lastmod>2026-08-31</lastmod><image:image><image:loc>https://media.stockwirex.com/land-for-sale-sign-scaled.jpg</image:loc><image:title>Aland Equity Group Locks In Rights to Sell 56 Lots Targeting $75K Net Per Lot</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/land-for-sale-sign-scaled.jpg</video:thumbnail_loc><video:title>Aland Equity Group Locks In Rights to Sell 56 Lots Targeting $75K Net Per Lot</video:title><video:description>Aland Equity Group Elm Grove Heights takes a major step forward as AEG executes its Management Rights Agreement over 56 residential lots in Bungendore, targeting $75,000 in Fund income per lot and a late September 2026 sales launch.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/ad5b113c.mp4</video:content_loc><video:publication_date>2026-08-31T07:27:48Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/x2m-connect-ai-data-centre-deal-august-2026-2</loc><lastmod>2026-08-28</lastmod><image:image><image:loc>https://media.stockwirex.com/Data-Center-Interior-9-scaled.jpg</image:loc><image:title>X2M Connect Ltd Lands First $250M+ AI Data Centre Contract</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/Data-Center-Interior-9-scaled.jpg</video:thumbnail_loc><video:title>X2M Connect Ltd Lands First $250M+ AI Data Centre Contract</video:title><video:description>X2M Connect has signed its first binding AI-enabled data centre contract worth an estimated $250m+ across a three-to-five-year delivery period, converting the first of a 150MW Australian prospect pipeline into committed revenue with recurring platform fees expected over the life of the facility.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fad8e43ee-295a-414f-ac6d-23813bf6b589.mp4.mp4</video:content_loc><video:publication_date>2026-08-28T10:40:50Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/gss-genetic-signatures-fy2026-financial-results-august-2026</loc><lastmod>2026-08-25</lastmod><image:image><image:loc>https://media.stockwirex.com/Laboratory-Interior-4-scaled.jpg</image:loc><image:title>Genetic Signatures Ltd Posts FY26 Loss Down 30% With FY27 Savings Ahead</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/Laboratory-Interior-4-scaled.jpg</video:thumbnail_loc><video:title>Genetic Signatures Ltd Posts FY26 Loss Down 30% With FY27 Savings Ahead</video:title><video:description>Genetic Signatures FY2026 Financial Results show a 30% narrowing of net loss to $14.0M, a debt-free $22.1M cash position, and $5M in annualised savings locked in for FY2027 — here's what investors need to know about the reset year.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fc16f9055-bb04-45a9-af0e-baa7ccd962a6.mp4.mp4</video:content_loc><video:publication_date>2026-08-25T07:48:57Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/industrials/ang-austin-engineering-hsbc-refinancing-2029-august-2026</loc><lastmod>2026-08-24</lastmod><image:image><image:loc>https://media.stockwirex.com/lobby-with-signage-scaled.jpg</image:loc><image:title>Austin Engineering Ltd Locks In $43.9M HSBC Refinancing to 2029</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/lobby-with-signage-scaled.jpg</video:thumbnail_loc><video:title>Austin Engineering Ltd Locks In $43.9M HSBC Refinancing to 2029</video:title><video:description>Austin Engineering has locked in a $43.9 million HSBC refinancing extending its banking facilities to November 2029 — here's what the Austin Engineering HSBC refinancing 2029 deal means for investors navigating the company's operational recovery.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/183f2438-1.mp4</video:content_loc><video:publication_date>2026-08-24T15:01:24Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/gss-genetic-signatures-hvidovre-hospital-denmark-contract-august-2026</loc><lastmod>2026-08-21</lastmod><image:image><image:loc>https://media.stockwirex.com/Lab-Interior-Display-scaled.jpg</image:loc><image:title>Genetic Signatures Ltd Activates Denmark Contract as Hospital Testing Begins</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/Lab-Interior-Display-scaled.jpg</video:thumbnail_loc><video:title>Genetic Signatures Ltd Activates Denmark Contract as Hospital Testing Begins</video:title><video:description>Genetic Signatures' Hvidovre Hospital Denmark contract has moved from signed agreement to live commercial testing, activating a ten-year recurring supply relationship anchored by 28,000 samples in year one.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F172bda74-fbc1-474a-803a-9af4efaafa13.mp4.mp4</video:content_loc><video:publication_date>2026-08-21T07:47:43Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/idt-australia-fy26-full-year-results-august-2026</loc><lastmod>2026-08-20</lastmod><image:image><image:loc>https://media.stockwirex.com/IDT-Factory-Interior-scaled.jpg</image:loc><image:title>IDT Australia Ltd Narrows FY26 EBITDA Loss 85% and Targets $50M FY29 Revenue</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/IDT-Factory-Interior-scaled.jpg</video:thumbnail_loc><video:title>IDT Australia Ltd Narrows FY26 EBITDA Loss 85% and Targets $50M FY29 Revenue</video:title><video:description>IDT Australia's FY26 full year results show an 85% narrowing of EBITDA losses to –$0.9M, 16.5% revenue growth to $16.8M, and a fully funded $7M capability investment targeting a $50M revenue run-rate by FY29.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fcaa8abd2-24a0-4c41-943f-f10e85648e0c.mp4.mp4</video:content_loc><video:publication_date>2026-08-20T09:12:25Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/industrials/mgh-maas-group-holdings-fy26-earnings-guidance-increase-august-2026</loc><lastmod>2026-08-04</lastmod><image:image><image:loc>https://media.stockwirex.com/factory_sign-scaled.jpg</image:loc><image:title>Maas Group Holdings Ltd Secures $855m Firmus Order and Lifts FY26 EBITDA Guidance</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/factory_sign-scaled.jpg</video:thumbnail_loc><video:title>Maas Group Holdings Ltd Secures $855m Firmus Order and Lifts FY26 EBITDA Guidance</video:title><video:description>Maas Group lifts its Maas Group FY26 earnings guidance increase to $300m–$310m EBITDA, anchored by an $855 million electrical infrastructure order for AI developer Firmus and a further $300 million equity stake in the company.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/15cb933e-1.mp4</video:content_loc><video:publication_date>2026-08-04T09:29:37Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/real-estate/aeg-aland-equity-group-elm-grove-heights-fund-july-2026</loc><lastmod>2026-07-31</lastmod><image:image><image:loc>https://media.stockwirex.com/AEG-Elm-Grove-Heights-scaled.jpg</image:loc><image:title>Aland Equity Group Ltd Launches Capital Light Model With Elm Grove Heights Deal</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/AEG-Elm-Grove-Heights-scaled.jpg</video:thumbnail_loc><video:title>Aland Equity Group Ltd Launches Capital Light Model With Elm Grove Heights Deal</video:title><video:description>Aland Equity Group's Elm Grove Heights Fund targets $75,000 in income per lot across 56 residential lots in Bungendore NSW — with no shareholder dilution and a non-recourse debt facility funding the project as the blueprint for the 3,200-lot Chinnerys development.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fefc94a79-7e33-4cb7-9e07-c3b354083b9e-2.mp4-2.mp4</video:content_loc><video:publication_date>2026-07-31T07:33:08Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imu-imugene-azer-cel-btki-trial-response-july-2026</loc><lastmod>2026-07-27</lastmod><image:image><image:loc>https://media.stockwirex.com/laboratory_with_signage-scaled.jpg</image:loc><image:title>Imugene Ltd Notches Third Response in Azer Cel BTKi Cohort</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/laboratory_with_signage-scaled.jpg</video:thumbnail_loc><video:title>Imugene Ltd Notches Third Response in Azer Cel BTKi Cohort</video:title><video:description>Imugene's azer-cel BTKi trial has now recorded three responses across five patients in its concurrent BTKi cohort — including both Follicular Lymphoma patients treated to date — strengthening the early efficacy signal in a heavily pre-treated population within a US$12 billion market.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F24191c1d-5098-4193-b4bc-a3b7796ca18f.mp4.mp4</video:content_loc><video:publication_date>2026-07-27T08:14:26Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/idt-australia-fy26-guidance-upgrade-july-2026</loc><lastmod>2026-07-21</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fimages2Farticles2Fphotorealistic-8k-hdr-cinematic-image-of-a-cutting-edge-pharmaceutical-biomanufacturing-fa-d5d110ec-scaled.jpg</image:loc><image:title>IDT Australia Ltd Lifts FY26 Guidance as Revenue Hits $16.8M and EBITDA Loss Narrows</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fimages2Farticles2Fphotorealistic-8k-hdr-cinematic-image-of-a-cutting-edge-pharmaceutical-biomanufacturing-fa-d5d110ec-scaled.jpg</video:thumbnail_loc><video:title>IDT Australia Ltd Lifts FY26 Guidance as Revenue Hits $16.8M and EBITDA Loss Narrows</video:title><video:description>IDT Australia (ASX: IDT) upgrades its FY26 guidance with revenue from three verticals climbing 16.5% to $16.8M and the EBITDA loss narrowing 85.1% to -$943K, as dual RNA manufacturing awards and a Sanofi Preferred Vendor designation reinforce the company's operational turnaround.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F029c2b3d-c824-4f3b-af6a-9b433337411f.mp4.mp4</video:content_loc><video:publication_date>2026-07-21T12:38:06Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/4dx-4dmedical-va-lung-imaging-bill-july-2026</loc><lastmod>2026-07-16</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F50ee8fd8-6e27-47e9-8f8b-bc44aecfe8a02Fimage_0-scaled.jpg</image:loc><image:title>4DMEDICAL Ltd Eyes US$20M Veterans Lung Imaging Pilot in Bipartisan Bill</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F50ee8fd8-6e27-47e9-8f8b-bc44aecfe8a02Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>4DMEDICAL Ltd Eyes US$20M Veterans Lung Imaging Pilot in Bipartisan Bill</video:title><video:description>A bipartisan US bill authorising US$20 million for a VA 4D lung imaging pilot has put 4DMedical's FDA-cleared XV LVAS® squarely in the frame — here's what investors need to know about the AIR CARE for Vets Act and what happens next.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fdc863c30-5498-4a53-a872-821bf2674906.mp4.mp4</video:content_loc><video:publication_date>2026-07-16T10:51:41Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imc-immuron-fy26-sales-growth-july-2026</loc><lastmod>2026-07-16</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F277adf25-75c7-41c7-9122-1c9b621267252Fimage_0-scaled.jpg</image:loc><image:title>Immuron Ltd Posts AUD$7.7M FY26 Sales After Four Quarters of Growth</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F277adf25-75c7-41c7-9122-1c9b621267252Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>Immuron Ltd Posts AUD$7.7M FY26 Sales After Four Quarters of Growth</video:title><video:description>Immuron's Travelan FY26 sales growth hit AUD$7.7 million across four consecutive quarters of year-on-year gains, with Australia up 10%, US USD growth at 13%, and Canada surging 427% in Q4.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F330200b3-f131-490f-b612-6ccfe1b4c27f.mp4.mp4</video:content_loc><video:publication_date>2026-07-16T08:44:41Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/1ai-algorae-pharmaceuticals-board-appointment-july-2026</loc><lastmod>2026-07-15</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fc2e5bc46-118e-4f4a-af83-4a9b296665f22Fimage_0-scaled.jpg</image:loc><image:title>Algorae Pharmaceuticals Ltd Appoints Nasdaq Pharma Chair Troy Valentine</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fc2e5bc46-118e-4f4a-af83-4a9b296665f22Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>Algorae Pharmaceuticals Ltd Appoints Nasdaq Pharma Chair Troy Valentine</video:title><video:description>Algorae Pharmaceuticals (ASX: 1AI) has appointed Troy Valentine — chairman of Nasdaq-listed Incannex Healthcare and architect of over A$220 million in capital raisings — as a Non-Executive Director to drive its dual AlgoraeRx and AlgoraeOS growth strategy.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F4df1914e-c028-4f71-99fa-b4d93d9d468e.mp4.mp4</video:content_loc><video:publication_date>2026-07-15T07:16:29Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imc-immuron-imm-529-cdi-partnering-july-2026</loc><lastmod>2026-07-06</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fce7cfc09-0087-4fd3-8a56-86ebd3a896c82Fimage_0-scaled.jpg</image:loc><image:title>Immuron Ltd Engages Pullan Consulting for IMM-529 Partnering Strategy</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fce7cfc09-0087-4fd3-8a56-86ebd3a896c82Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>Immuron Ltd Engages Pullan Consulting for IMM-529 Partnering Strategy</video:title><video:description>Immuron has engaged specialist firm Pullan Consulting to secure a strategic partner for IMM-529, its Phase 2-ready CDI therapy backed by an FDA-cleared IND and a projected US$400M base case revenue opportunity.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F1691de18-3454-4531-b1b8-b05c27d87f76.mp4.mp4</video:content_loc><video:publication_date>2026-07-06T07:37:32Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/1ai-algorae-pharmaceuticals-algoraeos-v2-validation-july-2026</loc><lastmod>2026-07-03</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fb9b14ab6-a11f-47ad-85bf-491be1bf9b582Fimage_0-scaled.jpg</image:loc><image:title>Algorae Pharmaceuticals Ltd AI Platform Validated With 2.5x Synergy Lift</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fb9b14ab6-a11f-47ad-85bf-491be1bf9b582Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>Algorae Pharmaceuticals Ltd AI Platform Validated With 2.5x Synergy Lift</video:title><video:description>Algorae Pharmaceuticals AlgoraeOS v2 validation by Peter MacCallum Cancer Centre confirms the upgraded AI platform identifies synergistic drug combinations at 2.5 times the rate of its predecessor, with a 9-million-prediction multi-anchor pipeline now underway.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fff26663c-9b77-49d2-972e-770eecbf4298.mp4.mp4</video:content_loc><video:publication_date>2026-07-03T07:20:38Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/gss-genetic-signatures-bcal-share-acquisition-july-2026</loc><lastmod>2026-07-02</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fb377bf6c-56e4-43e5-9dd1-8e08cd86e8c82Fimage_0-scaled.jpg</image:loc><image:title>Genetic Signatures Ltd Gets BCAL Backing Through 10.2% Stake Purchase</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fb377bf6c-56e4-43e5-9dd1-8e08cd86e8c82Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>Genetic Signatures Ltd Gets BCAL Backing Through 10.2% Stake Purchase</video:title><video:description>BCAL Diagnostics acquires a 10.2% stake in Genetic Signatures for $1.39 million, adding an FDA-cleared infectious disease diagnostics pillar to its oncology portfolio — here's what the Genetic Signatures BCAL share acquisition means for investors.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F1637525e-bc54-4ddb-b3be-54d1241fd880.mp4.mp4</video:content_loc><video:publication_date>2026-07-02T08:21:41Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/1ai-algorae-pharmaceuticals-nsw-health-supply-contract-july-2026</loc><lastmod>2026-07-02</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fbc5a1876-b4d2-41c9-ba61-5ceb353457682Fimage_0-scaled-1.jpg</image:loc><image:title>Algorae Pharmaceuticals Ltd Clarifies NSW Health Supply Panel Terms</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fbc5a1876-b4d2-41c9-ba61-5ceb353457682Fimage_0-scaled-1.jpg</video:thumbnail_loc><video:title>Algorae Pharmaceuticals Ltd Clarifies NSW Health Supply Panel Terms</video:title><video:description>Algorae Pharmaceuticals (ASX: 1AI) has clarified the terms of its Algorae Pharmaceuticals NSW Health contract, confirming AlgoraeRx as an approved supplier under a standing offer arrangement with first supply expected in Q4 2026 — here's what investors need to know.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fcada916a-efd0-4307-8e85-ec92746f1da4.mp4.mp4</video:content_loc><video:publication_date>2026-07-02T08:02:51Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imu-imugene-azer-cel-complete-response-july-2026</loc><lastmod>2026-07-01</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F352176a6-56e8-4d9b-a769-8060d34f35502Fimage_0-scaled.jpg</image:loc><image:title>Imugene Ltd Reports Second Complete Response in BTKi Cohort</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F352176a6-56e8-4d9b-a769-8060d34f35502Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>Imugene Ltd Reports Second Complete Response in BTKi Cohort</video:title><video:description>Imugene's azer-cel has now recorded two complete responses from two evaluable patients in its BTKi cohort — including the first Mantle Cell Lymphoma patient treated — targeting a US$12 billion market where resistance to standard therapy leaves patients with almost nowhere left to turn.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fb887ec34-ea8c-4b9d-a9c8-2f3a97141774.mp4.mp4</video:content_loc><video:publication_date>2026-07-01T08:17:05Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/1ai-algorae-pharmaceuticals-nsw-health-supply-contract-june-2026</loc><lastmod>2026-07-01</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fbc5a1876-b4d2-41c9-ba61-5ceb353457682Fimage_0-scaled.jpg</image:loc><image:title>Algorae Pharmaceuticals Ltd Wins NSW Health Public Hospital Supply Contract</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fbc5a1876-b4d2-41c9-ba61-5ceb353457682Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>Algorae Pharmaceuticals Ltd Wins NSW Health Public Hospital Supply Contract</video:title><video:description>Algorae Pharmaceuticals (ASX: 1AI) has won a competitive NSW Health public hospital supply contract through its AlgoraeRx division, securing up to five years of access to one of Australia's largest healthcare procurement networks with first supply expected in Q4 2026.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F1b61a210-e708-4dbe-b27e-2581fd480b74.mp4.mp4</video:content_loc><video:publication_date>2026-07-01T07:22:30Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imu-imugene-azer-cel-complete-response-btki-trial-june-2026</loc><lastmod>2026-06-30</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F2a344520-01d6-4afd-916a-2551a867724f2Fimage_0-scaled.jpg</image:loc><image:title>Imugene Ltd Reports First Complete Response in Azer Cel BTKi Cohort</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F2a344520-01d6-4afd-916a-2551a867724f2Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>Imugene Ltd Reports First Complete Response in Azer Cel BTKi Cohort</video:title><video:description>Imugene's azer-cel has achieved its first complete response in the BTKi combination cohort, with a Follicular Lymphoma patient who had previously failed BTKi therapy clearing disease at the Day 28 assessment — an early but significant signal in a US$12 billion market.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F7ed8274e-a152-47f5-a284-202a8080bf37.mp4.mp4</video:content_loc><video:publication_date>2026-06-30T10:02:48Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/1ai-algorae-pharmaceuticals-sovereign-ai-partnership-june-2026</loc><lastmod>2026-06-29</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F51e06b91-b6d6-4fd8-a8cf-bfd5f509483f2Fimage_0-scaled.jpg</image:loc><image:title>Algorae Pharmaceuticals Ltd Named Launch Partner in Sovereign AI Initiative</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F51e06b91-b6d6-4fd8-a8cf-bfd5f509483f2Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>Algorae Pharmaceuticals Ltd Named Launch Partner in Sovereign AI Initiative</video:title><video:description>Algorae Pharmaceuticals (ASX: 1AI) has secured the Algorae Pharmaceuticals Sovereign AI Partnership as healthcare launch partner in the NVIDIA-accelerated SAII initiative, positioning its AlgoraeOS platform at the centre of governed AI-enabled drug discovery in Australia.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F84e4ad04-d0f3-4be0-9286-b1213d733d1a.mp4.mp4</video:content_loc><video:publication_date>2026-06-29T07:20:16Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/vnl-vinyl-group-pedestrian-time-out-acquisition-june-2026</loc><lastmod>2026-06-26</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F63af0a40-ae97-46c2-9bc4-b7586eeecf172Fimage_0-scaled.jpg</image:loc><image:title>Vinyl Group Ltd Eyes First EBITDA Positive Year After Nominal Cost Deals</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F63af0a40-ae97-46c2-9bc4-b7586eeecf172Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>Vinyl Group Ltd Eyes First EBITDA Positive Year After Nominal Cost Deals</video:title><video:description>Vinyl Group (ASX: VNL) has acquired Pedestrian Group and Time Out Australia for nominal consideration, pushing its online reach to 55% of Australians and forecasting its first EBITDA-positive year in FY27 with $3.5 million on $37–$40 million revenue.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F77f96a76-66b9-4211-b308-335bb1b88ca7.mp4.mp4</video:content_loc><video:publication_date>2026-06-26T10:51:38Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/4dx-4dmedical-tga-approval-ctvq-june-2026</loc><lastmod>2026-06-26</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F4b441ec4-6a0c-4126-9905-694fe44735522Fimage_0-scaled.jpg</image:loc><image:title>4DMEDICAL Ltd Wins TGA Approval for Lung Imaging Tool in Australia</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F4b441ec4-6a0c-4126-9905-694fe44735522Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>4DMEDICAL Ltd Wins TGA Approval for Lung Imaging Tool in Australia</video:title><video:description>4DMedical (ASX:4DX) has secured TGA approval for its CT:VQ™ lung imaging solution, unlocking commercial deployment across Australia's world-leading CT scanner network and opening a Medicare reimbursement pathway.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fa9e6daed-713a-45a9-bfd1-4bffd9c51597.mp4.mp4</video:content_loc><video:publication_date>2026-06-26T06:37:17Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/financials/aeg-chinnerys-funding-deed-june-2026</loc><lastmod>2026-06-23</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fca7e4d41-9b57-4124-86c6-90c212988fab2Fimage_0-scaled.jpg</image:loc><image:title>Aland Equity Group Locks In 3,200-Lot Pipeline With Built-In 30% Profit Margins</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fca7e4d41-9b57-4124-86c6-90c212988fab2Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>Aland Equity Group Locks In 3,200-Lot Pipeline With Built-In 30% Profit Margins</video:title><video:description>Aland Equity Group has executed the Chinnerys Funding Deed, securing exclusive 20-year funding rights over 3,200 residential lots in the Canberra growth corridor with a contractually fixed 30% development margin worth approximately $174,000 per lot.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/0f9ae799-4.mp4</video:content_loc><video:publication_date>2026-06-23T07:58:24Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/financials/pvl-powerhouse-ventures-technology-fund-expansion</loc><lastmod>2026-06-22</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fab1a84c9-ad52-405a-891a-1b996538b9592Fimage_0-scaled.jpg</image:loc><image:title>Powerhouse Ven Ltd Targets USD100M Global Fund With European Partner</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fab1a84c9-ad52-405a-891a-1b996538b9592Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>Powerhouse Ven Ltd Targets USD100M Global Fund With European Partner</video:title><video:description>Powerhouse Ventures technology fund expansion takes a major leap as the company signs an MOU with a European venture firm to co-manage a USD100 million global Critical Infrastructure Opportunities Fund, with USD50 million already earmarked for a Q3 2026 launch.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F700d06b1-fc9d-4186-b503-1457244c9763.mp4.mp4</video:content_loc><video:publication_date>2026-06-22T07:28:56Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/gss-strategic-review-outcomes-cost-reduction-profitability-plan</loc><lastmod>2026-06-10</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F489fd606-9996-4a72-8e38-e2529b3a72ce2Fimage_0-scaled.jpg</image:loc><image:title>Genetic Signatures Details $5M Cost Cut and Three-Phase Path to Profitability</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F489fd606-9996-4a72-8e38-e2529b3a72ce2Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>Genetic Signatures Details $5M Cost Cut and Three-Phase Path to Profitability</video:title><video:description>Genetic Signatures has completed its 90-day strategic review, delivering a $5 million annualised cost reduction, two long-term supply agreements, and a three-horizon roadmap that charts a concrete path to profitability for ASX investors tracking Genetic Signatures strategic review outcomes.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fa2a4941c-3ab7-4bfa-b65b-0ec4ca53c202.mp4.mp4</video:content_loc><video:publication_date>2026-06-10T11:38:31Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imu-imugene-azer-cel-fda-fast-track-june-2026</loc><lastmod>2026-06-09</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F30062ad5-b204-43c4-8f92-049671692c372Fimage_0-scaled.jpg</image:loc><image:title>Imugene's Azer-cel Earns FDA Fast Track for Two Blood Cancers After 100% ORR</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F30062ad5-b204-43c4-8f92-049671692c372Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>Imugene's Azer-cel Earns FDA Fast Track for Two Blood Cancers After 100% ORR</video:title><video:description>Imugene's azer-cel has received dual FDA Fast Track Designation for two blood cancer indications, backed by Phase 1b data showing 100% ORR in CLL/SLL and 83% ORR in MZL, marking a significant regulatory milestone for the off-the-shelf CAR T programme.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F40aef7bf-a0b3-4b51-8c28-aa2718833c12.mp4.mp4</video:content_loc><video:publication_date>2026-06-09T09:41:09Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/myx-mayne-pharma-cosette-legal-settlement-june-2026-2</loc><lastmod>2026-06-05</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Ff8474ea9-53c9-4c1a-ade7-244a54f44cfe2Fimage_0-scaled.jpg</image:loc><image:title>Mayne Pharma Collects $14.4M in Cash From Cosette After Court Win</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Ff8474ea9-53c9-4c1a-ade7-244a54f44cfe2Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>Mayne Pharma Collects $14.4M in Cash From Cosette After Court Win</video:title><video:description>Mayne Pharma has received $14.4 million from Cosette Pharmaceuticals under a Supreme Court of NSW cost order, delivering a confirmed balance sheet benefit even as the Mayne Pharma Cosette legal settlement appeal decision remains pending.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fe032ead3-5f07-42f5-9189-b7f2536660b5.mp4.mp4</video:content_loc><video:publication_date>2026-06-05T20:04:36Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/4dx-4dmedical-clear-pe-market-entry-june-2026</loc><lastmod>2026-06-05</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F3b4cb8c8-7070-4531-b1fb-4e35555006fd2Fimage_0-scaled.jpg</image:loc><image:title>4DMedical Eyes $2.5B PE Market as CLEAR Program Targets 5M Annual US Scans</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F3b4cb8c8-7070-4531-b1fb-4e35555006fd2Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>4DMedical Eyes $2.5B PE Market as CLEAR Program Targets 5M Annual US Scans</video:title><video:description>4DMedical has launched the CLEAR program targeting the US$2.5 billion acute pulmonary embolism imaging market, partnering with Massachusetts General Hospital to build clinical evidence for its contrast-free CT:VQ™ technology and potentially expand its U.S. addressable market sixfold to US$3 billion.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F55bb16c7-5c35-44a5-85d5-a140a9e616d2.mp4.mp4</video:content_loc><video:publication_date>2026-06-05T17:54:58Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/enp-phase-2-bed-trial-cohort-1-completion-june-2026</loc><lastmod>2026-06-05</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F2e9fbe34-3e3a-43de-be67-c53fa1eb2eb52Fimage_0-scaled.jpg</image:loc><image:title>Entropy Neurodynamics Completes Dosing for Six Patients in Phase 2 BED Trial</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F2e9fbe34-3e3a-43de-be67-c53fa1eb2eb52Fimage_0-scaled.jpg</video:thumbnail_loc><video:title>Entropy Neurodynamics Completes Dosing for Six Patients in Phase 2 BED Trial</video:title><video:description>Entropy Neurodynamics (ASX: ENP) has completed Cohort 1 dosing in its Phase 2 BED trial for TRP-8803, with all six participants achieving controlled, reproducible psychedelic responses and topline efficacy data expected in July 2026.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/4d4753d9.mp4</video:content_loc><video:publication_date>2026-06-05T15:36:01Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/4dx-4dmedical-clear-program-pe-market-june-2026</loc><lastmod>2026-06-02</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F6b8db415-7c86-454e-a8fc-0a274e03516a2Fimage_0.jpg-scaled.jpg</image:loc><image:title>4DMedical Eyes $2.5B Pulmonary Market With Contrast-Free Imaging Tech</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F6b8db415-7c86-454e-a8fc-0a274e03516a2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>4DMedical Eyes $2.5B Pulmonary Market With Contrast-Free Imaging Tech</video:title><video:description>4DMedical's CLEAR programme targets the US$2.5 billion pulmonary embolism market with a contrast-free CT:VQ™ alternative to CTPA, potentially multiplying the company's addressable U.S. market sixfold to US$3 billion.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fa3744ac6-1d84-4c01-ad3a-91810f6864b5.mp4.mp4</video:content_loc><video:publication_date>2026-06-02T09:47:21Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/4dx-contextflow-acquisition-european-expansion-2026</loc><lastmod>2026-06-01</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F13ab5dc5-6c5a-4aaf-8b43-fac100a6d50b2Fimage_0.jpg-scaled.jpg</image:loc><image:title>4DMedical Acquires contextflow for European Expansion at 6.5% of Cash Balance</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F13ab5dc5-6c5a-4aaf-8b43-fac100a6d50b2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>4DMedical Acquires contextflow for European Expansion at 6.5% of Cash Balance</video:title><video:description>4DMedical (ASX: 4DX) acquires Austrian AI imaging firm contextflow GmbH for approximately A$18.56 million cash, instantly expanding its European footprint and growing its addressable respiratory imaging market by 50% for just 6.5% of existing cash reserves.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F809562ab-bb97-4b47-a923-d832fbb1cb36.mp4.mp4</video:content_loc><video:publication_date>2026-06-01T07:46:01Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imu-imugene-azer-cel-asco-2026-presentation-may-2026</loc><lastmod>2026-06-01</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fd755782e-b212-4090-a8a0-55fc20082bd82Fimage_0.jpg-scaled.jpg</image:loc><image:title>Imugene's Azer-cel Earns Rare Oral Slot at ASCO From 8,500+ Submissions</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fd755782e-b212-4090-a8a0-55fc20082bd82Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Imugene's Azer-cel Earns Rare Oral Slot at ASCO From 8,500+ Submissions</video:title><video:description>Imugene's azer-cel ASCO 2026 data secured a rare oral presentation slot from 8,500+ submissions, delivering response rates of up to 100% across six blood cancer subtypes in a Phase 1b CAR-T naïve cohort.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fe76054e9-e9d9-4bdd-b368-88286e1d0217.mp4.mp4</video:content_loc><video:publication_date>2026-06-01T06:53:56Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imu-imugene-azer-cel-btki-combo-trial-may-2026</loc><lastmod>2026-05-30</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fc82224d8-a07b-4245-8593-97e8ddb0b4ab2Fimage_0.jpg-scaled.jpg</image:loc><image:title>Imugene Doses First Patient in BTKi Combo Cohort of Azer-Cel Cancer Trial</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fc82224d8-a07b-4245-8593-97e8ddb0b4ab2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Imugene Doses First Patient in BTKi Combo Cohort of Azer-Cel Cancer Trial</video:title><video:description>Imugene has dosed the first patient in its azer-cel BTKi combination trial cohort, targeting a US$12 billion market of BTKi-relapsed B-cell malignancy patients with limited treatment options.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F70f08f53-e47f-4a90-8355-657d9833993f.mp4.mp4</video:content_loc><video:publication_date>2026-05-30T17:17:59Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/4dx-4dmedical-simonmed-imaging-partnership-may-2026</loc><lastmod>2026-05-30</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F8c7b6680-4233-4249-91b4-97b914e9078a2Fimage_0.jpg-scaled.jpg</image:loc><image:title>4DMedical Secures Commercial SimonMed Contract Across 170 US Imaging Centres</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F8c7b6680-4233-4249-91b4-97b914e9078a2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>4DMedical Secures Commercial SimonMed Contract Across 170 US Imaging Centres</video:title><video:description>4DMedical (ASX: 4DX) has secured a landmark three-year commercial agreement with SimonMed Imaging to deploy CT:VQ™ and LDAf™ across more than 170 US outpatient imaging centres, marking a pivotal shift from academic validation to scaled commercial revenue generation.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F2a139f10-bc89-48e7-9637-153a0d21a451.mp4.mp4</video:content_loc><video:publication_date>2026-05-30T17:04:34Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/financials/aeg-property-pipeline-transaction-may-2026</loc><lastmod>2026-05-27</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F6775e576-93bd-4e07-b8f9-396e74db0d862Fimage_0.jpg-scaled.jpg</image:loc><image:title>Aland Equity Group Targets Recurring Fees From 4,200 Lot Development Pipeline</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F6775e576-93bd-4e07-b8f9-396e74db0d862Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Aland Equity Group Targets Recurring Fees From 4,200 Lot Development Pipeline</video:title><video:description>Aland Equity Group (ASX: AEG) has secured a 4,200+ lot property pipeline across NSW and ACT growth corridors under 10 + 10 year exclusivity agreements, positioning the company to generate recurring fee income through wholesale property funds without carrying development risk.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F50093a43-928f-4473-941d-d5d8fef310f0.mp4.mp4</video:content_loc><video:publication_date>2026-05-27T08:03:23Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/pck-painchek-uk-sales-growth-march-2026</loc><lastmod>2026-05-26</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F60943da2-836c-42b5-a20c-441bf5eb67b62Fimage_0.jpg-scaled.jpg</image:loc><image:title>PainChek Locks In 4,000 UK Licences as Care Homes Prioritise Pain Tech</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F60943da2-836c-42b5-a20c-441bf5eb67b62Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>PainChek Locks In 4,000 UK Licences as Care Homes Prioritise Pain Tech</video:title><video:description>PainChek secured 4,000 new UK licences in Q3 FY26, delivering 9% quarter-on-quarter growth and $230,000 AUD in additional ARR as PainChek UK sales growth accelerates across the aged care sector.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F560bd4e9-df49-474b-8daa-a9ecac963040.mp4.mp4</video:content_loc><video:publication_date>2026-05-26T13:52:42Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/industrials/imb-q3-update-27-percent-pipeline-growth-may-2026</loc><lastmod>2026-05-26</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F4984823c-bb5e-4fd2-8842-684d8a280b482Fimage_0.jpg-scaled.jpg</image:loc><image:title>Intelligent Monitoring Group Details 27% Pipeline Jump and Eyes AI Security Expansion</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F4984823c-bb5e-4fd2-8842-684d8a280b482Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Intelligent Monitoring Group Details 27% Pipeline Jump and Eyes AI Security Expansion</video:title><video:description>Intelligent Monitoring Group Q3 Update reveals a 27% quarter-on-quarter pipeline surge to $63.2 million, 14.5% operating cashflow growth, and reaffirmed FY26 EBITDA guidance of $43-47 million — signalling strong commercial momentum for ASX investors.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fae7752aa-a0d7-4144-913b-dac6acf96764.mp4.mp4</video:content_loc><video:publication_date>2026-05-26T13:28:06Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imu-imugene-azer-cel-asco-results-may-2026</loc><lastmod>2026-05-22</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Ffd79d043-9ce8-4134-aa46-2c87ff1d91122Fimage_0.jpg-scaled.jpg</image:loc><image:title>Imugene's Azer-Cel Hits 81% Response Rate in CAR T-Naive Blood Cancer Patients</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Ffd79d043-9ce8-4134-aa46-2c87ff1d91122Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Imugene's Azer-Cel Hits 81% Response Rate in CAR T-Naive Blood Cancer Patients</video:title><video:description>Imugene's azer-cel delivered an 81% overall response rate in CAR T-naïve blood cancer patients across six subtypes, with full Phase 1b data set for oral presentation at ASCO 2026 on 29 May.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F5caae675-ecc2-4688-85be-f09ffe4ff597.mp4.mp4</video:content_loc><video:publication_date>2026-05-22T13:40:11Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/4dx-4dmedical-ctvq-lung-surgery-validation-may-2026</loc><lastmod>2026-05-19</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F3b61b0e3-b549-49a8-ac77-87b7c84a91c32Fimage_0.jpg-scaled.jpg</image:loc><image:title>4DMedical Study Shows Its CT:VQ Tech Nearly Doubles Lung Surgery Success Rates</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F3b61b0e3-b549-49a8-ac77-87b7c84a91c32Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>4DMedical Study Shows Its CT:VQ Tech Nearly Doubles Lung Surgery Success Rates</video:title><video:description>4DMedical's CT:VQ lung surgery validation published in the world's top respiratory journal demonstrates a 76% surgical response rate versus 46% under current methods, nearly doubling successful outcomes for emphysema patients.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F4eefa2d5-4f31-41c1-8eeb-0db36c3b2e57.mp4.mp4</video:content_loc><video:publication_date>2026-05-19T13:37:30Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/1ai-algorae-pharmaceuticals-ai-drug-pipeline-may-2026</loc><lastmod>2026-05-18</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Ffe35f3af-f426-459e-8cb5-ebb877c5c7ef2Fimage_0.jpg-scaled.jpg</image:loc><image:title>Algorae Scales AI Platform to 18 Anchor Drugs With 9M+ Synergy Predictions</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Ffe35f3af-f426-459e-8cb5-ebb877c5c7ef2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Algorae Scales AI Platform to 18 Anchor Drugs With 9M+ Synergy Predictions</video:title><video:description>Algorae Pharmaceuticals has supercharged its AI drug pipeline by scaling AlgoraeOS v2 to 18 anchor drugs, generating over 9 million synergy predictions and identifying more than 6,000 biologically robust drug combinations for further evaluation.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fa2b7e3d2-f411-46e4-b958-d498e7996e87.mp4.mp4</video:content_loc><video:publication_date>2026-05-18T07:05:16Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/financials/mme-moneyme-365m-abs-transaction-may-2026</loc><lastmod>2026-05-15</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F0b147dd5-a694-4f72-be4f-1d6174004a232Fimage_0.jpg-scaled.jpg</image:loc><image:title>MoneyMe Closes Record $365M ABS Deal to Fund Growth at Lower Funding Costs</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F0b147dd5-a694-4f72-be4f-1d6174004a232Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>MoneyMe Closes Record $365M ABS Deal to Fund Growth at Lower Funding Costs</video:title><video:description>MoneyMe has closed its largest-ever personal loan ABS transaction at $365.4 million — an 80% increase on its prior record — bringing total FY26 ABS issuance to over $1 billion and signalling accelerating institutional confidence in the fintech lender's loan book.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fa6d6f70b-7f75-45bc-be11-e1bafd1fa433.mp4.mp4</video:content_loc><video:publication_date>2026-05-15T11:44:11Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/nxn-nexsen-ghk-hospital-partnership-may-2026</loc><lastmod>2026-05-13</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F6110ffe5-06e8-4975-83b5-120d1f23ada12Fimage_0.jpg-scaled.jpg</image:loc><image:title>Nexsen Secures GHK's 500-Bed Hong Kong Hospital for Asia Diagnostic Validation</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F6110ffe5-06e8-4975-83b5-120d1f23ada12Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Nexsen Secures GHK's 500-Bed Hong Kong Hospital for Asia Diagnostic Validation</video:title><video:description>Nexsen has secured its first Asia hospital partnership through a binding term sheet with GHK Hospital Limited, unlocking potential access to IHH Healthcare's 190-facility network across 10 countries for clinical validation of its rapid point-of-care diagnostics.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F3813ba5c-a392-4353-96c8-e32208823035.mp4.mp4</video:content_loc><video:publication_date>2026-05-13T10:21:02Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/iov-patent-portfolio-monetisation-assessment-may-2026</loc><lastmod>2026-05-11</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F3f07c012-5a34-4b7b-b396-34d5f07c847b2Fimage_0.jpg-scaled.jpg</image:loc><image:title>ION Video's Patent Portfolio Earns High Monetisation Score From Global IP Firm</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F3f07c012-5a34-4b7b-b396-34d5f07c847b2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>ION Video's Patent Portfolio Earns High Monetisation Score From Global IP Firm</video:title><video:description>ION Video has received an independent IP assessment from global law firm Elevate, scoring the company's patent portfolio within a range indicating higher relative monetisation potential across reference-based video architecture, distributed ledger transactions, and tokenised delivery systems.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F2ccd86da-866b-46a7-ae43-eeb05afb1c99.mp4.mp4</video:content_loc><video:publication_date>2026-05-11T08:44:09Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/financials/mqg-macquarie-group-record-profit-fy26-may-2026</loc><lastmod>2026-05-08</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fab4447fd-cc9c-4a45-8996-1769ce07f4ad2Fimage_0.jpg-scaled.jpg</image:loc><image:title>Macquarie Group Reports Record $4.85B Profit With All Four Divisions Growing</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fab4447fd-cc9c-4a45-8996-1769ce07f4ad2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Macquarie Group Reports Record $4.85B Profit With All Four Divisions Growing</video:title><video:description>Macquarie Group's FY26 profit result hit a record $4.85 billion — up 30% on FY25 — driven by broad-based double-digit growth across all four operating divisions and a landmark second-half earnings surge of 93%.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fab19469d-efcb-42b0-8fdb-5a94352a9f53.mp4.mp4</video:content_loc><video:publication_date>2026-05-08T10:27:50Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/pvl-critical-infrastructure-fund-launch-may-2026</loc><lastmod>2026-05-06</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F79619986-5b7b-463e-8fee-434c29a7a40e2Fimage_0.jpg-scaled.jpg</image:loc><image:title>Powerhouse Ven Launches Critical Infrastructure Fund With $13M Seed Portfolio</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F79619986-5b7b-463e-8fee-434c29a7a40e2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Powerhouse Ven Launches Critical Infrastructure Fund With $13M Seed Portfolio</video:title><video:description>Powerhouse Ventures (ASX: PVL) has launched the Critical Infrastructure Opportunities Fund targeting Space, Quantum, AI, and Advanced Materials with an $13 million seed portfolio across 11 companies and a $75 million capital raise target.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F91bab8b5-af3e-4a59-8459-e72168edd2ee.mp4.mp4</video:content_loc><video:publication_date>2026-05-06T12:36:46Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/1ai-algorae-torrent-pharma-license-agreement-may-2026</loc><lastmod>2026-05-06</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fc4427229-1a8c-45cb-b4c7-33a179854ceb2Fimage_0.jpg-scaled.jpg</image:loc><image:title>Algorae Locks In Deal With $1.7B Torrent to Fast-Track Generic Drugs to Market</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fc4427229-1a8c-45cb-b4c7-33a179854ceb2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Algorae Locks In Deal With $1.7B Torrent to Fast-Track Generic Drugs to Market</video:title><video:description>Algorae Pharmaceuticals (ASX: 1AI) has secured an Algorae Torrent Pharma License Agreement covering two generic prescription molecules for the Australian and New Zealand markets, marking the company's sixth commercial deal through its AlgoraeRx subsidiary.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fc4a72762-f54c-4c70-b351-5b42096e637f.mp4.mp4</video:content_loc><video:publication_date>2026-05-06T07:04:40Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/eye-nova-eye-medical-sales-guidance-upgrade-may-2026</loc><lastmod>2026-05-05</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fbeb4ea4c-b3e7-4615-a154-d90ffc34e1cb2Fimage_0.jpg-scaled.jpg</image:loc><image:title>Nova Eye Lifts FY26 Sales Guidance to US$22-23M After Record USA Sales in April</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fbeb4ea4c-b3e7-4615-a154-d90ffc34e1cb2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Nova Eye Lifts FY26 Sales Guidance to US$22-23M After Record USA Sales in April</video:title><video:description>Nova Eye Medical upgrades FY26 sales guidance to US$22–23 million after April 2026 set a new monthly USA sales record, with trailing twelve-month sales (excluding China) surging 27% to US$21.6 million.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F225d069e-2958-4652-89d4-34c38ac64a01.mp4.mp4</video:content_loc><video:publication_date>2026-05-05T10:29:59Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/avh-avita-medical-recell-go-regulatory-clearance-april-2026</loc><lastmod>2026-04-30</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F17d89ecf-fd74-4ff5-93b9-04c820928fa62Fimage_0.jpg-scaled.jpg</image:loc><image:title>AVITA Medical Clears RECELL GO for Launch in Australia and New Zealand Markets</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F17d89ecf-fd74-4ff5-93b9-04c820928fa62Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>AVITA Medical Clears RECELL GO for Launch in Australia and New Zealand Markets</video:title><video:description>AVITA Medical has secured TGA certification in Australia and Medsafe WAND listing in New Zealand for RECELL GO, unlocking imminent commercial launch through Revolution Surgical and expanding the automated burn treatment system's regulatory footprint across five major developed markets.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F4dbad772-41ea-4fa0-97cb-4380fca87128.mp4.mp4</video:content_loc><video:publication_date>2026-04-30T11:02:22Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/emd-emyria-nsw-expansion-matilda-healthcare-april-2026</loc><lastmod>2026-04-29</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F32c94f52-6530-4bb2-b1cc-ecb12223f2cf2Fimage_0.jpg-scaled.jpg</image:loc><image:title>Emyria Expands Into NSW With 4-Bed Psychedelics Clinic Targeting 2.5M Catchment</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F32c94f52-6530-4bb2-b1cc-ecb12223f2cf2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Emyria Expands Into NSW With 4-Bed Psychedelics Clinic Targeting 2.5M Catchment</video:title><video:description>Emyria's Empax NSW expansion into Matilda Nepean Private Hospital adds four new treatment beds and brings the national psychedelic-assisted therapy network to 18 beds across five states, targeting a catchment of over 2.5 million people in Western Sydney.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F77c64c04-1ba1-4b3f-9faa-d4fde1cbda98.mp4.mp4</video:content_loc><video:publication_date>2026-04-29T09:22:03Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/acr-acrux-female-testosterone-hsdd-april-2026</loc><lastmod>2026-04-28</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F4f7a98f6-7516-49c9-9ba1-34bbce3ebcc92Fimage_0.jpg-scaled.jpg</image:loc><image:title>Acrux Eyes $2.9Bn US Market Opening With Female Testosterone for Underserved HSDD</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F4f7a98f6-7516-49c9-9ba1-34bbce3ebcc92Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Acrux Eyes $2.9Bn US Market Opening With Female Testosterone for Underserved HSDD</video:title><video:description>Acrux Limited (ASX: ACR) has pivoted its strategy to advance Acrux Female Testosterone for HSDD, targeting a US$2.88 billion US market with no FDA-approved competitor and a product launch roadmap extending to late FY28.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fc41791a1-4764-42c6-97dc-036568666be6.mp4.mp4</video:content_loc><video:publication_date>2026-04-28T10:19:04Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/idt-australia-sanofi-preferred-vendor-status-april-2026</loc><lastmod>2026-04-28</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F8f28901d-8b06-4adf-867b-066a3d39c4952Fimage_0.jpg-scaled.jpg</image:loc><image:title>IDT Australia Eyes Best Quarter in Two Years as Sanofi Partnership Pays Off</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F8f28901d-8b06-4adf-867b-066a3d39c4952Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>IDT Australia Eyes Best Quarter in Two Years as Sanofi Partnership Pays Off</video:title><video:description>IDT Australia's Sanofi Preferred Vendor designation, combined with 68%-76% forecast EBITDA improvement and US policy tailwinds for controlled substances, positions the CDMO for its strongest quarter since beginning its strategic transformation.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F07a7fdaf-984c-4a7a-bf5a-cea2a5129b2b.mp4.mp4</video:content_loc><video:publication_date>2026-04-28T08:16:09Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/1ai-algorae-pharmaceuticals-zydus-deal-april-2026</loc><lastmod>2026-04-28</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F27e75f29-20ce-41d6-8b9d-23859902f8362Fimage_0.jpg-scaled.jpg</image:loc><image:title>Algorae Locks In Exclusive Deal for 10 Pharma Products From Global Giant Zydus</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F27e75f29-20ce-41d6-8b9d-23859902f8362Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Algorae Locks In Exclusive Deal for 10 Pharma Products From Global Giant Zydus</video:title><video:description>Algorae Pharmaceuticals (ASX: 1AI) has secured an exclusive Algorae Zydus Commercial Agreement ANZ covering 10 pharmaceutical products across Australia and New Zealand, building a multi-product revenue pipeline without internal manufacturing costs.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fbac3136f-f224-4cc2-85b6-ab659189af13.mp4.mp4</video:content_loc><video:publication_date>2026-04-28T07:47:29Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/cuv-clinuvel-phase-iii-vitiligo-study-april-2026</loc><lastmod>2026-04-24</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F07ce1fff-3a3b-498c-b6c4-f1bb71329f6d2Fimage_0.jpg-scaled.jpg</image:loc><image:title>Clinuvel Secures EMA Scientific Advice for 300Patient Vitiligo Study</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F07ce1fff-3a3b-498c-b6c4-f1bb71329f6d2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Clinuvel Secures EMA Scientific Advice for 300Patient Vitiligo Study</video:title><video:description>Clinuvel Pharmaceuticals has secured EMA scientific advice for its Clinuvel Phase III Vitiligo Study, clearing the regulatory pathway for a 300-patient pivotal trial of SCENESSE set to commence in the second half of 2026.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fc5853ae4-360c-4d34-9b44-2b7fa240cd9c.mp4.mp4</video:content_loc><video:publication_date>2026-04-24T16:21:09Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/cmb-cambium-bio-fda-single-trial-pathway-april-2026</loc><lastmod>2026-04-24</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F110bb254-abc6-460c-b865-aa6bd5c0aa0f2Fimage_0.jpg-scaled.jpg</image:loc><image:title>Cambium Bio Cuts Path to FDA Approval From Two Trials Down to One for Dry Eye Drug</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F110bb254-abc6-460c-b865-aa6bd5c0aa0f2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Cambium Bio Cuts Path to FDA Approval From Two Trials Down to One for Dry Eye Drug</video:title><video:description>Cambium Bio (ASX: CMB) has secured FDA confirmation that a single pivotal Phase 3 trial is an acceptable pathway to a Biologics License Application for Elate Ocular, materially reducing capital requirements and accelerating the timeline to potential market authorisation for moderate-to-severe dry eye disease.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F7f907c7e-9037-4e6e-a037-7524ba68288d.mp4.mp4</video:content_loc><video:publication_date>2026-04-24T14:48:25Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/rce-recce-pharmaceuticals-phase-3-inspection-april-2026</loc><lastmod>2026-04-21</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F94a26c99-de05-4e6e-a478-f0a075efcf6e2Fimage_0.jpg-scaled.jpg</image:loc><image:title>Recce Pharma Clears Indonesian Inspection for Phase 3 Diabetic Foot Trial</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F94a26c99-de05-4e6e-a478-f0a075efcf6e2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Recce Pharma Clears Indonesian Inspection for Phase 3 Diabetic Foot Trial</video:title><video:description>Recce Pharmaceuticals' Phase 3 inspection in Indonesia has cleared a critical regulatory hurdle with no findings from Badan POM, advancing RECCE® 327's pathway toward CY26 marketing approval in a US$1.5 billion Asia-Pacific market.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fb43bd7eb-fedf-47b9-af3e-6e629e5d4883.mp4.mp4</video:content_loc><video:publication_date>2026-04-21T13:32:18Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/hfy-hubify-hublab-ai-investment-april-2026</loc><lastmod>2026-04-20</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fb2343468-b167-4561-a32f-853a3845179d2Fimage_0.jpg-scaled.jpg</image:loc><image:title>Hubify Completes $250K Investment in Australian AI RegTech Venture HubLab</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fb2343468-b167-4561-a32f-853a3845179d2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Hubify Completes $250K Investment in Australian AI RegTech Venture HubLab</video:title><video:description>Hubify has completed a $250,000 strategic investment in Australian AI venture HubLab, securing exclusive access to Labrynth's regulatory AI platform and positioning itself as the execution layer for enterprise compliance solutions across Australia's third-largest RegTech market.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F13f33d5c-325d-4855-a3f9-e7c9ec480a54.mp4.mp4</video:content_loc><video:publication_date>2026-04-20T19:14:46Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/dxn-cable-landing-station-contract-april-2026</loc><lastmod>2026-04-20</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F7ba7f6a7-92c4-4350-9ec3-fb481ec0c3fc2Fimage_0.jpg-scaled.jpg</image:loc><image:title>DXN Lands $5.3M Contract to Build Cable Landing Station in South America</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F7ba7f6a7-92c4-4350-9ec3-fb481ec0c3fc2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>DXN Lands $5.3M Contract to Build Cable Landing Station in South America</video:title><video:description>DXN Limited (ASX: DXN) secures a A$5.3 million DXN cable landing station contract with a repeat global internet company customer, marking the company's first entry into the Latin American market with commissioning targeted for Q1 CY2027.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F37a03b46-c360-44fc-af65-4df01a64c0ff.mp4.mp4</video:content_loc><video:publication_date>2026-04-20T10:40:19Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/occ-orthocell-first-dod-remplir-surgery-april-2026</loc><lastmod>2026-04-17</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Ff12304f5-4c7c-4b74-a247-350b864456f62Fimage_0.jpg-scaled.jpg</image:loc><image:title>Orthocell Completes First Remplir Surgery in US Military Hospital System</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Ff12304f5-4c7c-4b74-a247-350b864456f62Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Orthocell Completes First Remplir Surgery in US Military Hospital System</video:title><video:description>Orthocell has achieved its first Remplir DoD surgical use just days after procurement approval, unlocking access to 221 US military and veteran hospitals through a rapidly activated distributor network.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F69647428-c789-4e26-ad70-cf9a58c4c3ff.mp4.mp4</video:content_loc><video:publication_date>2026-04-17T10:01:17Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imc-immuron-q3-sales-growth-april-2026</loc><lastmod>2026-04-17</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F6a104e9d-ac79-4ca2-a457-439d0d5cdf8a2Fimage_0.jpg-scaled.jpg</image:loc><image:title>Immuron Posts 16% Q3 Sales Growth as Travelan Gains Traction in Three Markets</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F6a104e9d-ac79-4ca2-a457-439d0d5cdf8a2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Immuron Posts 16% Q3 Sales Growth as Travelan Gains Traction in Three Markets</video:title><video:description>Immuron Q3 sales growth hit 16% year-on-year to AUD$1.5 million as Travelan accelerates across Australia, Canada, and the US — here's what investors need to know.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F82082415-1ab3-4d83-9f66-7b0f37a44d1b.mp4.mp4</video:content_loc><video:publication_date>2026-04-17T07:40:39Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/industrials/aqn-aquirian-48m-brightstar-contract-april-2026</loc><lastmod>2026-04-16</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fc6b815d7-c8ec-4538-b3ce-5f80787e43a02Fimage_0.jpg-scaled.jpg</image:loc><image:title>Aquirian Locks In $48M Drilling Contract With Path to Two More Gold Mine Sites</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fc6b815d7-c8ec-4538-b3ce-5f80787e43a02Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Aquirian Locks In $48M Drilling Contract With Path to Two More Gold Mine Sites</video:title><video:description>Aquirian's Drillforce WA subsidiary has secured a $48 million, three-year drilling contract with Brightstar Resources for the Lord Byron gold mine, underpinned by a Strategic Framework Agreement covering three Goldfields Hub sites with significant expansion potential.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F756961d1-3eb2-42bd-9115-48b344ab4443.mp4.mp4</video:content_loc><video:publication_date>2026-04-16T10:48:58Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/qor-10m-aura-facility-merger-vote-july-2026</loc><lastmod>2026-04-15</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F3f55cb4d-7d67-4f50-bf89-71092c79df4a2Fimage_0.jpg-scaled.jpg</image:loc><image:title>Qoria Receives $10M Aura Facility as Merger Workstreams Advance to July Vote</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F3f55cb4d-7d67-4f50-bf89-71092c79df4a2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Qoria Receives $10M Aura Facility as Merger Workstreams Advance to July Vote</video:title><video:description>Qoria has secured a $10 million unsecured working capital facility from Aura as the Qoria Aura merger update confirms a July 2026 shareholder vote and a target of positive free cash flow by December 2026.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F8605fbbf-bf42-4a4a-a757-b6c4428c3096.mp4.mp4</video:content_loc><video:publication_date>2026-04-15T09:46:09Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/rnv-nervalign-matrix-stage-3-verification-fda-2026</loc><lastmod>2026-04-15</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Facfce8a3-ec57-4042-bded-9eb96687d9c72Fimage_0.jpg-scaled.jpg</image:loc><image:title>ReNerve Advances Nerve Replacement Tech to Stage 3 Verification for FDA Path</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Facfce8a3-ec57-4042-bded-9eb96687d9c72Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>ReNerve Advances Nerve Replacement Tech to Stage 3 Verification for FDA Path</video:title><video:description>ReNerve Limited's NervAlign Nerve Guide Matrix has entered Stage 3 verification — the critical penultimate phase before FDA submission — targeting a USD$2 billion global nerve repair market.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F6f8f11ca-7a66-45d7-a706-b095e6a83b29.mp4.mp4</video:content_loc><video:publication_date>2026-04-15T09:33:48Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/tlx-telix-pharmaceuticals-550m-bond-refinancing-april-2026</loc><lastmod>2026-04-14</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fc22d3963-fc52-4268-aa07-ad97339875002Fimage_0.jpg-scaled.jpg</image:loc><image:title>Telix Launches US$550M Convertible Bond Refinancing to Push Debt Out to 2031</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fc22d3963-fc52-4268-aa07-ad97339875002Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Telix Launches US$550M Convertible Bond Refinancing to Push Debt Out to 2031</video:title><video:description>Telix Pharmaceuticals launches a US$550 million convertible bond refinancing due 2031, extending its debt maturity and securing cost-effective non-dilutive capital at a coupon of just 1.50%–1.75% to fund its global radiopharmaceutical expansion.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F98d9f0fc-cafc-4f71-a6d5-aabc7db1112a.mp4.mp4</video:content_loc><video:publication_date>2026-04-14T15:18:57Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/sen-senetas-south-america-encryption-sale-april-2026</loc><lastmod>2026-04-14</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fea491a5e-65c9-4e2b-bf4e-098ce50f59eb2Fimage_0.jpg-scaled.jpg</image:loc><image:title>Senetas Lands $2.5M South American Deal in Its Biggest Virtual Encryption Win</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fea491a5e-65c9-4e2b-bf4e-098ce50f59eb2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Senetas Lands $2.5M South American Deal in Its Biggest Virtual Encryption Win</video:title><video:description>Senetas Corporation has completed a landmark US$1.7 million Senetas South America encryption sale to a government agency — its largest ever virtualised encryption deal — while a previously delayed Middle East transaction also clears, delivering a combined A$2.2–2.4 million profit before tax contribution to FY2026.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/ee72ad70.mp4</video:content_loc><video:publication_date>2026-04-14T09:42:00Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/ams-atomos-flanders-scientific-acquisition-april-2026</loc><lastmod>2026-04-13</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fa3d9e7d0-867a-43c9-8b2b-8441f72f28662Fimage_0.jpg-scaled.jpg</image:loc><image:title>Atomos Acquires Flanders Scientific to Capture Higher Margin Monitor Market</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fa3d9e7d0-867a-43c9-8b2b-8441f72f28662Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Atomos Acquires Flanders Scientific to Capture Higher Margin Monitor Market</video:title><video:description>Atomos Limited (ASX: AMS) acquires Flanders Scientific to expand into high-margin professional reference monitors, with the deal immediately earnings accretive and funded via a $10 million CBA facility.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F9a49005a-ba29-4e82-94a0-436332e1e400.mp4.mp4</video:content_loc><video:publication_date>2026-04-13T10:12:30Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/tlx-pixclara-fda-nda-acceptance-september-2026-decision</loc><lastmod>2026-04-10</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F26dacade-529f-46ce-9dbf-252a5728e8b62Fimage_0.jpg-scaled.jpg</image:loc><image:title>Telix's Pixclara Brain Cancer Scan Wins FDA Review With September Decision Date</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F26dacade-529f-46ce-9dbf-252a5728e8b62Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Telix's Pixclara Brain Cancer Scan Wins FDA Review With September Decision Date</video:title><video:description>Telix Pharmaceuticals (ASX: TLX) has secured FDA acceptance of its resubmitted Pixclara NDA, setting an 11 September 2026 PDUFA decision date for the glioma imaging agent that carries both Orphan Drug and Fast Track designations.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F265e2fe7-ec20-4e32-b8df-3744061b5c9a.mp4.mp4</video:content_loc><video:publication_date>2026-04-10T10:12:06Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/industrials/mnd-monadelphous-145m-contract-wins-april-2026</loc><lastmod>2026-04-10</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F59730201-3741-4f14-bd41-03f75a5ef2002Fimage_0.jpg-scaled.jpg</image:loc><image:title>Monadelphous Secures $145M in Contracts Across Rio Tinto BHP and Harmony Gold</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F59730201-3741-4f14-bd41-03f75a5ef2002Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Monadelphous Secures $145M in Contracts Across Rio Tinto BHP and Harmony Gold</video:title><video:description>Monadelphous $145 Million Contract Wins across four separate awards and extensions with Rio Tinto, BHP, Queensland Alumina Limited, and Harmony Gold deliver medium-term revenue visibility and validate the engineering services giant's competitive positioning across Australia and Papua New Guinea.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F50cdc67a-281a-4203-ad97-b4a084ed00bb.mp4.mp4</video:content_loc><video:publication_date>2026-04-10T09:37:44Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/iod-iodm-limited-us-universities-platform-deal-april-2026</loc><lastmod>2026-04-09</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F0797660a-412b-4af1-805d-e51202e43ed62Fimage_0.jpg-scaled.jpg</image:loc><image:title>IODM Lands Platform Deal Spanning 283 US Universities With Path to 1,000</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F0797660a-412b-4af1-805d-e51202e43ed62Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>IODM Lands Platform Deal Spanning 283 US Universities With Path to 1,000</video:title><video:description>IODM Limited (ASX: IOD) has secured the IODM US Universities Platform Deal, unlocking access to 283 American universities through a one-to-many deployment model that management says could bring forward the company's cash flow positive timeline.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F906b09ec-36ec-4d9d-bb27-1111c6e7c8f0.mp4.mp4</video:content_loc><video:publication_date>2026-04-09T13:40:25Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/renewable-energy/del-delorean-corporation-bioenergy-fid-april-2026</loc><lastmod>2026-04-08</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fc7288192-ab65-4e8c-bbd1-006152dcfeb82Fimage_0.jpg-scaled.jpg</image:loc><image:title>Delorean Locks In $62M Bioenergy Project With $31M Government Backing Secured</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fc7288192-ab65-4e8c-bbd1-006152dcfeb82Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Delorean Locks In $62M Bioenergy Project With $31M Government Backing Secured</video:title><video:description>Delorean Corporation (ASX: DEL) has reached a Final Investment Decision for the $62.1 million Delorean Horsley Park Bioenergy Facility, with nearly 50% of construction costs already secured through ARENA and NSW Government grants, targeting first gas delivery by Q2 CY2028.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Ff27968eb-6673-476f-8aba-57b4c51837de.mp4.mp4</video:content_loc><video:publication_date>2026-04-08T14:03:17Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/nxt-nextdc-hybrid-securities-offer-april-2026</loc><lastmod>2026-04-07</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fc257dc2f-03d3-41e9-8a9d-1e7734c224242Fimage_0.jpg-scaled.jpg</image:loc><image:title>NEXTDC Launches $1B Hybrid Offer Backed by Binding $1B Commitment from La Caisse</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fc257dc2f-03d3-41e9-8a9d-1e7734c224242Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>NEXTDC Launches $1B Hybrid Offer Backed by Binding $1B Commitment from La Caisse</video:title><video:description>NEXTDC has launched a $1.0 billion Hybrid Securities Offer backed by a binding commitment from La Caisse, a CAD $517 billion global investor, boosting pro-forma liquidity to approximately $5.2 billion to fund its contracted data centre pipeline through FY29.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F5f13d0b6-ceed-4ed1-a181-ab917cea5553.mp4.mp4</video:content_loc><video:publication_date>2026-04-07T20:25:32Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/industrials/ect-environmental-clean-technologies-pfas-water-treatment-april-2026</loc><lastmod>2026-04-07</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F04cf6658-9255-4622-bbd1-08b270332fd82Fimage_0.jpg-scaled.jpg</image:loc><image:title>ECT Expands PFAS Tech Into Water Treatment With $10k Licence Add-On From Rice Uni</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F04cf6658-9255-4622-bbd1-08b270332fd82Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>ECT Expands PFAS Tech Into Water Treatment With $10k Licence Add-On From Rice Uni</video:title><video:description>ECT expands its Flash Joule Heating licence with Rice University to target PFAS-contaminated granular activated carbon in water treatment systems, opening a significant new addressable market alongside its existing soil remediation platform.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F9a1c5a97-9615-4027-ac48-4a8db39cb090.mp4.mp4</video:content_loc><video:publication_date>2026-04-07T12:06:57Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/rce-brazil-patent-grant-anti-infectives-march-2026</loc><lastmod>2026-03-24</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fdbcbc4dc-0444-4019-8932-9b94b2d0bcb12Fimage_0.jpg-scaled.jpg</image:loc><image:title>Recce Pharmaceuticals Locks In Brazilian Patent Protection Through 2041</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fdbcbc4dc-0444-4019-8932-9b94b2d0bcb12Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Recce Pharmaceuticals Locks In Brazilian Patent Protection Through 2041</video:title><video:description>Recce Pharmaceuticals Brazil patent grant secures Family 4 protection for R327 and R529 anti-infectives through 2041 in South America's largest antibiotics market, expanding the company's global IP portfolio to seven jurisdictions.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fcdce127a-6985-44cd-ae3f-33cf864531c6.mp4.mp4</video:content_loc><video:publication_date>2026-03-24T11:48:04Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/rhy-rhythm-biosciences-colostrat-rollout-march-2026</loc><lastmod>2026-03-19</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F85687ab1-d844-4625-8a48-5709c854631f2Fimage_0.jpg-scaled.jpg</image:loc><image:title>Rhythm Biosciences Activates 38 Sites to Scale Cancer Blood Test Commercially</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F85687ab1-d844-4625-8a48-5709c854631f2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Rhythm Biosciences Activates 38 Sites to Scale Cancer Blood Test Commercially</video:title><video:description>Rhythm Biosciences has activated 38 blood collection sites across Queensland, New South Wales and Victoria through its 4Cyte Pathology partnership, marking a pivotal milestone in the Rhythm Biosciences ColoSTAT Commercial Rollout as the company shifts from validation to volume-building phase.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F9a0a256a-9389-4a46-ac68-24e7df521de6.mp4.mp4</video:content_loc><video:publication_date>2026-03-19T07:23:54Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imu-imugene-raises-20m-azer-cel-funding-march-2026</loc><lastmod>2026-03-11</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fa077e5cc-e0ec-4086-b555-bc0148fb32d02Fimage_0.jpg-scaled.jpg</image:loc><image:title>Imugene Launches $20M Raise to Expand Blood Cancer Therapy Trial Into 2026</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fa077e5cc-e0ec-4086-b555-bc0148fb32d02Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Imugene Launches $20M Raise to Expand Blood Cancer Therapy Trial Into 2026</video:title><video:description>Imugene azer-cel clinical development funding receives a $20 million boost via institutional placement, SPP, and restructured convertible notes — extending the company's runway into Q4 2026 as it expands its Phase 1b CAR T trial with a new BTKi combination cohort.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F60599743-1098-4f8b-885b-a2870120c337.mp4.mp4</video:content_loc><video:publication_date>2026-03-11T20:42:01Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imu-imugene-azer-cel-phase-1b-results-march-2026</loc><lastmod>2026-03-10</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F57d4de02-cb6d-4403-8f19-97d4d9a681382Fimage_0.jpg-scaled.jpg</image:loc><image:title>Imugene's Off-the-Shelf CAR T Hits 100% Response Rate in Blood Cancer Trial</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F57d4de02-cb6d-4403-8f19-97d4d9a681382Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Imugene's Off-the-Shelf CAR T Hits 100% Response Rate in Blood Cancer Trial</video:title><video:description>Imugene azer-cel response rates hit 100% in CLL/SLL and 80% in MZL from its Phase 1b basket study, marking a significant early efficacy signal for this off-the-shelf allogeneic CAR T therapy across multiple B-cell malignancies.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/5f2efbf3.mp4</video:content_loc><video:publication_date>2026-03-10T10:42:59Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imc-immuron-coffee-microcaps-march-2026-presentation</loc><lastmod>2026-03-05</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F10462f1c-1f9c-4734-a818-03b25e54aeb82Fimage_0.jpg-scaled.jpg</image:loc><image:title>Immuron Seeks Partners for US$400M CDI Asset as Commercial Sales Grow 5% to A$4.2M</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F10462f1c-1f9c-4734-a818-03b25e54aeb82Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>Immuron Seeks Partners for US$400M CDI Asset as Commercial Sales Grow 5% to A$4.2M</video:title><video:description>Immuron CEO outlines strategic pivot to partnering model for IMM-124E and IMM-529 clinical assets at Coffee Microcaps Conference, with A$10 million cash providing 22.5 months runway and 1H FY26 sales up 5%.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fed8303a6-af6a-4664-97a2-633b8405e603-3.mp4-3.mp4</video:content_loc><video:publication_date>2026-03-05T06:38:08Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/1cg-fy2025-results-record-revenue-first-profit</loc><lastmod>2026-03-04</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F34f063b3-fd03-4df2-ac3b-20d27aa8435c2Fimage_0.jpg-scaled.jpg</image:loc><image:title>One Click Group Posts Record $6.1M Revenue and First-Ever Underlying EBITDA Profit</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F34f063b3-fd03-4df2-ac3b-20d27aa8435c2Fimage_0.jpg-scaled.jpg</video:thumbnail_loc><video:title>One Click Group Posts Record $6.1M Revenue and First-Ever Underlying EBITDA Profit</video:title><video:description>One Click Group (ASX: 1CG) reports record $6.1 million revenue and first-ever positive underlying EBITDA in FY2025, marking a critical inflection point as the fintech platform transitions to self-funding profitability with 230,000+ registered users.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fcff017b2-8ea3-4261-a024-eaff5ac6049a.mp4.mp4</video:content_loc><video:publication_date>2026-03-04T12:40:31Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/imc-immuron-fda-approval-c-diff-trial-february-2026</loc><lastmod>2026-02-26</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F14a67055-0b6c-4881-ac2b-5b985c1723692Fimage_0.png.png</image:loc><image:title>Immuron Grows Sales 5% to $4.2M and Wins FDA Approval for C. Diff Trial</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F14a67055-0b6c-4881-ac2b-5b985c1723692Fimage_0.png.png</video:thumbnail_loc><video:title>Immuron Grows Sales 5% to $4.2M and Wins FDA Approval for C. Diff Trial</video:title><video:description>Immuron delivers 5% global sales growth to $4.2 million and secures FDA approval for IMM-529 C. diff trial, with $10 million cash providing 23.5 months runway as it pursues partnering strategy.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F0b1f1ad8-3834-4aa9-ab6d-38cad4b9e26a.mp4.mp4</video:content_loc><video:publication_date>2026-02-26T08:06:06Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/ccg-record-fy26-h1-performance-revenue-ebitda-surge</loc><lastmod>2026-02-25</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fe0132d45-6096-45dc-94b8-096b8d41ac262Fimage_0.png.png</image:loc><image:title>Comms Group Revenue Surges 39% to $37.6M With EBITDA Doubling to Record $4.5M</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fe0132d45-6096-45dc-94b8-096b8d41ac262Fimage_0.png.png</video:thumbnail_loc><video:title>Comms Group Revenue Surges 39% to $37.6M With EBITDA Doubling to Record $4.5M</video:title><video:description>Comms Group reports record 1H FY26 with revenue up 39% to $37.6m and EBITDA surging 87% to $4.5m, reaffirming $75m+ revenue guidance and declaring maiden interim dividend.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F443452d3-eefb-4584-9a8a-e293564c082d.mp4.mp4</video:content_loc><video:publication_date>2026-02-25T17:32:55Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/oda-orcoda-1h-fy26-results-february-2026</loc><lastmod>2026-02-25</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fea41fc48-3129-4602-8acf-aa7e4175e3982Fimage_0.png.png</image:loc><image:title>Orcoda Delivers 130% EBITDA Surge as Recurring Revenue Climbs to $5.4M</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fea41fc48-3129-4602-8acf-aa7e4175e3982Fimage_0.png.png</video:thumbnail_loc><video:title>Orcoda Delivers 130% EBITDA Surge as Recurring Revenue Climbs to $5.4M</video:title><video:description>Orcoda Limited reports 130% EBITDA surge to $146,000 in 1H FY26, with annual recurring revenue climbing 20% to $5.4 million as the SaaS-driven transport technology company narrows losses and approaches breakeven.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fe5fccdf3-e264-48b9-b7d0-9eaf34efd9f6.mp4.mp4</video:content_loc><video:publication_date>2026-02-25T08:23:38Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/auk-aumake-ezz-distribution-deal-february-2026-2</loc><lastmod>2026-02-19</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F57e207e6-fd20-42d1-b387-d6aa6c3be4102Fimage_0.jpg.jpg</image:loc><image:title>Aumake Wins $10M Exclusive Distribution Deal for EZZ Life Science Products</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F57e207e6-fd20-42d1-b387-d6aa6c3be4102Fimage_0.jpg.jpg</video:thumbnail_loc><video:title>Aumake Wins $10M Exclusive Distribution Deal for EZZ Life Science Products</video:title><video:description>EZZ Life Science secures a four-year exclusive global distribution agreement with Aumake, featuring $10 million minimum purchase commitments and $2.5 million annual floors whilst retaining full IP ownership.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F48610309-b202-49af-9a9f-924cd094458b.mp4.mp4</video:content_loc><video:publication_date>2026-02-19T14:27:40Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/idt-australia-interim-results-h1-fy26-february-2026</loc><lastmod>2026-02-18</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fe6ec4f13-eceb-45ed-a90d-75f58df1e9be2Fimage_0.png.png</image:loc><image:title>IDT Australia Cuts EBITDA Loss 84% to $436K as API Revenue Surges 191%</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fe6ec4f13-eceb-45ed-a90d-75f58df1e9be2Fimage_0.png.png</video:thumbnail_loc><video:title>IDT Australia Cuts EBITDA Loss 84% to $436K as API Revenue Surges 191%</video:title><video:description>IDT Australia reports H1 FY26 turnaround with EBITDA loss narrowing 84% to $436K, API manufacturing surging 191%, and cost savings target doubled to $2M as the company targets positive operating profit.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F37bb5f08-b6c3-4ce6-856c-039261d92bdd.mp4.mp4</video:content_loc><video:publication_date>2026-02-18T09:39:14Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/cu6-clarity-pharmaceuticals-co-psma-trial-results-february-2026</loc><lastmod>2026-02-16</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F42afe129-a9b4-4c8b-98aa-5378c6f69a0b2Fimage_0.png.png</image:loc><image:title>Clarity Pharmaceuticals Diagnostic Detects 2.6x More Prostate Lesions Than Standard</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F42afe129-a9b4-4c8b-98aa-5378c6f69a0b2Fimage_0.png.png</video:thumbnail_loc><video:title>Clarity Pharmaceuticals Diagnostic Detects 2.6x More Prostate Lesions Than Standard</video:title><video:description>Clarity Pharmaceuticals' Co-PSMA trial reveals its 64Cu-SAR-bisPSMA diagnostic detected 2.6x more prostate cancer lesions than standard-of-care, with patient detection rates doubling to 78% versus 36%.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2Fdd06803a-92f2-4ce5-a905-fa335062ee14.mp4.mp4</video:content_loc><video:publication_date>2026-02-16T08:24:46Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/financials/asx-ceo-helen-lofthouse-transition-may-2026</loc><lastmod>2026-02-10</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F547dd134-8bf9-4c68-8104-e54f7c18beb12Fimage_0.png.png</image:loc><image:title>ASX CEO Helen Lofthouse to Step Down in May 2026 After CHESS Delivery</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F547dd134-8bf9-4c68-8104-e54f7c18beb12Fimage_0.png.png</video:thumbnail_loc><video:title>ASX CEO Helen Lofthouse to Step Down in May 2026 After CHESS Delivery</video:title><video:description>ASX CEO Helen Lofthouse will step down in May 2026 following the CHESS Release 1 go-live, with Korn Ferry engaged for a global search as the Board confirms continuity of all strategic initiatives.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F58f6a160-78bf-4203-916f-f5593189f05d.mp4.mp4</video:content_loc><video:publication_date>2026-02-10T18:23:56Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/industrials/bwn-riverside-acquisition-ebitda-growth-february-2026</loc><lastmod>2026-02-09</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F36a05906-8f81-4533-8fac-a16453daca612Fimage_0.png.png</image:loc><image:title>Bhagwan Marine Secures $120M Riverside Acquisition to Boost EBITDA by 54%</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F36a05906-8f81-4533-8fac-a16453daca612Fimage_0.png.png</video:thumbnail_loc><video:title>Bhagwan Marine Secures $120M Riverside Acquisition to Boost EBITDA by 54%</video:title><video:description>Bhagwan Marine announces $120 million acquisition of Riverside Marine Holdings, delivering 54% EBITDA uplift and 14% EPS accretion through capital-light vessel management across five diversified brands.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F43acca16-5040-4d0d-bcc6-76216182e96b.mp4.mp4</video:content_loc><video:publication_date>2026-02-09T09:19:01Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/bio-biome-australia-bmb18-clinical-trial-approval-february-2026</loc><lastmod>2026-02-04</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fc41ed2c5-fef8-4ee5-9ca5-4327a78900682Fimage_0.png.png</image:loc><image:title>Biome Australia Secures Ethics Approval for 240-Patient BMB18 Probiotic Trial</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fc41ed2c5-fef8-4ee5-9ca5-4327a78900682Fimage_0.png.png</video:thumbnail_loc><video:title>Biome Australia Secures Ethics Approval for 240-Patient BMB18 Probiotic Trial</video:title><video:description>Biome Australia secures ethics approval for its landmark BMB18 clinical trial, clearing the final regulatory hurdle for a 240-participant study investigating the proprietary probiotic strain's efficacy across digestive, mood, and sleep applications commencing February 2026.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F35a52be3-6da1-4944-b760-d1ec31261084.mp4.mp4</video:content_loc><video:publication_date>2026-02-04T15:53:15Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/ila-island-pharma-9m-galidesivir-fda-biodefense-funding-2026</loc><lastmod>2026-02-04</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F1330f66f-59b1-4a0f-b689-7d6a4f67f0af2Fimage_0.png.png</image:loc><image:title>Island Pharmaceuticals Raises $9M to Fund Marburg Antiviral Through FDA Approval</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F1330f66f-59b1-4a0f-b689-7d6a4f67f0af2Fimage_0.png.png</video:thumbnail_loc><video:title>Island Pharmaceuticals Raises $9M to Fund Marburg Antiviral Through FDA Approval</video:title><video:description>Island Pharmaceuticals secures $9m strategic placement to fully fund Galidesivir through FDA Animal Rule pathway, unlocking potential US Government stockpile eligibility and Priority Review Voucher opportunity.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F22fe1168-618d-4fd6-bbac-dde4e39c96b6.mp4.mp4</video:content_loc><video:publication_date>2026-02-04T15:53:15Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/acw-actinogen-medical-xanamia-trial-milestone-january-2026</loc><lastmod>2026-01-30</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2Fff2ef416-7208-4080-bff5-3bcd52c9a5b52Fimage_0.png.png</image:loc><image:title>Actinogen Medical XanaMIA Alzheimer's Trial Clears Key DMC Review to Final Results</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2Fff2ef416-7208-4080-bff5-3bcd52c9a5b52Fimage_0.png.png</video:thumbnail_loc><video:title>Actinogen Medical XanaMIA Alzheimer's Trial Clears Key DMC Review to Final Results</video:title><video:description>Actinogen Medical receives positive DMC recommendation to continue XanaMIA Alzheimer's trial without amendment after independent review of unblinded efficacy data, validating trial integrity ahead of pivotal November 2026 results.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F59e5f13f-3672-47ff-8aa4-03989832533c.mp4.mp4</video:content_loc><video:publication_date>2026-01-30T09:21:37Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/nvq-coralia-biochar-acquisition-90-percent-stake</loc><lastmod>2026-01-28</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F075dcd4b-6ffb-4d5d-9351-3bf7d1a254ab2Fimage_0.png.png</image:loc><image:title>NoviqTech Acquires 90% of Coralia Biochar for $1.5M Targeting 2025 Revenues</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F075dcd4b-6ffb-4d5d-9351-3bf7d1a254ab2Fimage_0.png.png</video:thumbnail_loc><video:title>NoviqTech Acquires 90% of Coralia Biochar for $1.5M Targeting 2025 Revenues</video:title><video:description>NoviqTech acquires 90% of Coralia for $1.5M, targeting data centre carbon removal demand with biochar CDR credits as AI infrastructure drives 6% of Australia's east coast grid by 2030.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F410fca09-ff5a-4f28-bac8-00ed8314aaef.mp4.mp4</video:content_loc><video:publication_date>2026-01-28T15:40:22Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/technology/oda-orcoda-cash-flow-positive-january-2025</loc><lastmod>2026-01-21</lastmod><image:image><image:loc>https://media.stockwirex.com/veo32Fnanobanana2F0a27e812-8ebc-4054-b552-a0add62b384c2Fimage_0.png.png</image:loc><image:title>Orcoda Swings to $1.14M Operating Cash Flow Positive After Cost Restructure</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/veo32Fnanobanana2F0a27e812-8ebc-4054-b552-a0add62b384c2Fimage_0.png.png</video:thumbnail_loc><video:title>Orcoda Swings to $1.14M Operating Cash Flow Positive After Cost Restructure</video:title><video:description>Orcoda Limited (ASX: ODA) achieved $1.14 million operating cash flow positive in Q3 with $767,000 free cash flow, marking a decisive turnaround as both divisions drive revenue growth and management pivots to AI-powered expansion.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F51c63a59-4e77-4cca-a26a-c3fdb4eeef09.mp4.mp4</video:content_loc><video:publication_date>2026-01-21T17:12:46Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/at1-atomo-diagnostics-liver-test-licensing-january-2026</loc><lastmod>2026-01-20</lastmod><image:image><image:loc>https://media.stockwirex.com/tmpa6uvpifd.jpg-scaled.jpg</image:loc><image:title>Atomo Diagnostics Secures Global Liver Test Rights Through 2044 for Pascal</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/tmpa6uvpifd.jpg-scaled.jpg</video:thumbnail_loc><video:title>Atomo Diagnostics Secures Global Liver Test Rights Through 2044 for Pascal</video:title><video:description>Atomo Diagnostics (ASX: AT1) secures exclusive global licensing for a novel liver function test through 2044, with pharmaceutical validation already underway via a 20,000-cassette clinical trial order.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F4b76294b-c0f0-4fc5-8dc7-d499812ef0e4.mp4.mp4</video:content_loc><video:publication_date>2026-01-20T10:47:41Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/rce-recce-pharmaceuticals-hong-kong-patent-january-2025</loc><lastmod>2026-01-19</lastmod><image:image><image:loc>https://media.stockwirex.com/tmpypacq5hi.jpg-scaled.jpg</image:loc><image:title>Recce Pharmaceuticals Secures Hong Kong Patent for Anti-Infectives Until 2041</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/tmpypacq5hi.jpg-scaled.jpg</video:thumbnail_loc><video:title>Recce Pharmaceuticals Secures Hong Kong Patent for Anti-Infectives Until 2041</video:title><video:description>Recce Pharmaceuticals secures Hong Kong patent protection for RECCE 327 and 529 anti-infectives until 2041, strengthening Asia-Pacific IP strategy as Phase 3 Indonesia trials advance in US$2.5 billion pharmaceutical market.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/c8b8d295-6.mp4</video:content_loc><video:publication_date>2026-01-19T15:04:25Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/consumer-staples/cco-calmer-co-record-december-sales-january-2026</loc><lastmod>2026-01-15</lastmod><image:image><image:loc>https://media.stockwirex.com/tmp25vepw2u.jpg-scaled.jpg</image:loc><image:title>Calmer Co Posts Record $910k Month as US FDA Ruling Opens Kava Market</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/tmp25vepw2u.jpg-scaled.jpg</video:thumbnail_loc><video:title>Calmer Co Posts Record $910k Month as US FDA Ruling Opens Kava Market</video:title><video:description>Calmer Co (ASX: CCO) posts record $910,767 monthly revenue with wholesale sales surging past FY25 totals as FDA regulatory clarity opens US retail expansion opportunities.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/6d3142b1.mp4</video:content_loc><video:publication_date>2026-01-15T10:02:49Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/1ad-adalta-car-t-therapy-placement-january-2026</loc><lastmod>2026-01-13</lastmod><image:image><image:loc>https://media.stockwirex.com/tmpw1qrqopc.jpg-scaled.jpg</image:loc><image:title>AdAlta Raises $1.2M at 67% Premium to Advance Licensed PD1 CAR-T Therapy</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/tmpw1qrqopc.jpg-scaled.jpg</video:thumbnail_loc><video:title>AdAlta Raises $1.2M at 67% Premium to Advance Licensed PD1 CAR-T Therapy</video:title><video:description>AdAlta (ASX: 1AD) raises $1.2 million at a 67% premium to advance its licensed PD1 armoured CAR-T therapy BZDS1901 and expand its "East to West" cellular immunotherapy strategy targeting solid tumours.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F4f3a8f1e-4529-46b9-9b5f-3346cccd0a5b.mp4.mp4</video:content_loc><video:publication_date>2026-01-13T14:26:15Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/financials/fnd-72m-nova-global-strategic-investment-2026</loc><lastmod>2026-01-12</lastmod><image:image><image:loc>https://media.stockwirex.com/tmps_xfrgc6.jpg-scaled.jpg</image:loc><image:title>Findi Ltd Secures $72M Investment to Accelerate Indian ATM and Payments Growth</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/tmps_xfrgc6.jpg-scaled.jpg</video:thumbnail_loc><video:title>Findi Ltd Secures $72M Investment to Accelerate Indian ATM and Payments Growth</video:title><video:description>Findi Limited secures a binding $72 million strategic investment from Nova Global for its Indian subsidiary TSI, funding ATM network expansion and digital payments scaling with first tranche closing February 2026.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F15ca30a2-5388-4576-9186-44c35be81c63.mp4.mp4</video:content_loc><video:publication_date>2026-01-12T21:22:50Z</video:publication_date></video:video></url><url><loc>http://bedrock.stockwirex.com/asx-videos/healthcare/cyc-cyclopharm-technegas-colombia-approval-january-2026</loc><lastmod>2026-01-12</lastmod><image:image><image:loc>https://media.stockwirex.com/tmpfq55b6d5.jpg-scaled.jpg</image:loc><image:title>Cyclopharm Secures Colombia Approval for Technegas in 67th Country Ahead of 2026 Summit</image:title></image:image><video:video><video:thumbnail_loc>https://media.stockwirex.com/tmpfq55b6d5.jpg-scaled.jpg</video:thumbnail_loc><video:title>Cyclopharm Secures Colombia Approval for Technegas in 67th Country Ahead of 2026 Summit</video:title><video:description>Cyclopharm secures Technegas approval in Colombia, its 67th country milestone, strategically timed ahead of the WFNMB Congress in Cartagena to accelerate AI-enabled functional lung imaging adoption across Latin America.</video:description><video:content_loc>https://storage.googleapis.com/media.stockwirex.com/video-concat2F1ffdf5bc-2097-4dea-bcc2-e17e90b7c975.mp4.mp4</video:content_loc><video:publication_date>2026-01-12T19:49:00Z</video:publication_date></video:video></url></urlset>